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Abstract 
The adoptive cell therapy (ACT) represents one promising and realistic strategy to 
treat cancer patients trough cancer immunotherapy. This clinical approach 
consists in the transfer of CD8+ T lymphocytes, specific for tumor antigens. The 
effectiveness of ACT so far is limited by crucial events as the trafficking of 
adoptively transferred cells to the tumor site and the highly immunosuppressive 
environment of developing cancer.  
Tumors are complex and flexible lesions where cancer cells and host immune 
cells dynamically interact. The immunosuppressive functions are exerted by 
distinct cell populations as myeloid derived suppressor cells (MDSCs) and tumor 
associated macrophages (TAMs) that are known to suppress T cell proliferation in 
several ways. One is based on the coordinated up regulation and activity of two 
specific enzymes: arginase (ARG1) and nitric oxide synthase type 2 (NOS2 or 
iNOS). At the tumor site, ARG1 induces the depletion of the amino acid L-
arginine that is necessary for T cell activation and proliferation. NOS2 is 
responsible for the generation of nitric oxide (NO) and other reactive nitrogen 
species (RNS). These free radicals are known to impair T cell functions within the 
tumor. Additionally, our group recently described a novel tumor-associated 
immunosuppressive mechanism based on post-translational modifications of 
chemokines by RNS. NO has dual role in cancer biology because it can promote 
both tumor progression as well as tumor regression. NO induces tumor 
progression and metastasis by direct induction of tumor-cell proliferation, 
migration and invasion, and indirectly through the expression of angiogenic and 
lymphangiogenic factors in tumor cells. On the other hand, high doses of NO have 
cytotoxic effects, which can result in tumor regression and metastasis inhibition. 
This dichotomous behavior mainly depends on the quantity, location, and timing 
of NO production and on the cellular sensitivity to this radical.   
The primary aim of the study was elucidate the role of NOS2 and its principal 
product NO in the tumor microenvironment and more specifically in the ACT 
approach. To this purpose, we performed in vivo experiments of ACT in either 
wild type or Nos2 knock-out mouse models, challenged with a tumor cell line 
expressing the OVA antigen. Instrumental for dissecting the role of NO in ACT 
was the setting of a valuable tools whether to monitor in real-time NO release by 
confocal microscopy on viable tumor slices after T cell interaction or sorting 
isolation of specific population responsible for NO induction after ACT. 
Our study proposed an innovative approach to study NO dynamics within intact 
tumor microenvironment. Our approach was instrumental for the definition -for 
the first time in tumors- of a new subset of myeloid population, named TNF/iNOS 
producing dendritic cells (Tip-DCs), with antitumor activity mediated by NOS2 
and consequently NO. Mostly important our study brought the awareness that 
NOS2 is fundamental for the effectiveness of ACT, opening new perspectives to 
improve cancer immunotherapy based on NOS2/NO modulation in tumors. 
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Riassunto 
L’immunoterapia cellulare adottiva (indicata di seguito con l’acronimo inglese 
ACT) oggi rappresenta una promettente strategia per il trattamento di pazienti 
affetti da cancro. Quest’approccio clinico consiste nel trasferimento adottivo di 
linfociti T CD8+, specifici per gli antigeni tumorali. L’efficacia dell’ACT è 
limitata da alcuni eventi fondamentali come il richiamo delle cellule trasferite nel 
sito tumorale e l’ambiente molto immunosoppressivo in cui si sviluppa il cancro. 
I tumori sono delle lesioni complesse e dinamiche, nelle quali  le cellule 
neoplastiche interagiscono con le cellule del sistema immunitario dell’ospite. Nel 
tumore,  l’immunosoppressione è mediata da alcune popolazioni cellulari come le 
cellule mieloidi e i macrofagi associati al tumore, noti per sopprimere la 
proliferazione delle cellule T in diversi modi. Uno di questi è la sovraespressione 
e l’attività coordinata di due enzimi: l’arginasi (ARG1) e l’ossido nitrico sintasi 2 
(NOS2 o iNOS). Nel sito tumorale ARG1 induce la deplezione dell’aminoacido 
L-arginina, necessaria per l’attivazione e la proliferazione delle cellule T. NOS2 è 
responsabile della sintesi dell’ossido nitrico e altre specie reattive dell’azoto. 
Questi radicali liberi sono noti bloccare le funzioni delle cellule T nel tumore. 
Inoltre, il nostro gruppo recentemente ha descritto un nuovo meccanismo 
d’immunosoppressione associato al tumore basato sulle modifiche post-
traduzionali indotte dalle specie reattive dell’azoto sulle chemochine. L’ossido 
nitrico ha un duplice ruolo nella biologia del cancro poiché può promuovere come 
inibire la progressione tumorale. L’ossido nitrico induce la progressione tumorale 
e le metastasi agendo direttamente sulla proliferazione e migrazione delle cellule 
tumorali e indirettamente attraverso l’espressione di fattori angiogenici e 
linfoangiogenici. Tuttavia, una elevata concentrazione di ossido nitrico può 
causare effetti citotossici che possono condurre alla regressione tumorale e 
l’inibizione delle metastasi. Questa dicotomia dipende principalmente dalla 
quantità, dalla localizzazione e dalla cinetica di generazione dell’ossido nitrico e 
soprattutto dalla sensibilità cellulare all’esposizione di questo radicale.  
L’obiettivo primario di questo studio è stato di delucidare il ruolo di NOS2 e del 
suo principale prodotto (ossido nitrico) nel microambiente tumorale, in particolare 
nell’approccio clinico dell’ immunoterapia cellulare adottiva. Abbiamo svolto 
esperimenti di trasferimento adottivo sia nel modello animale wild type che nel 
modello Nos2 knock-out, nei quali si è indotto lo sviluppo di tumori mediante  l' 
inoculo di una linea tumorale esprimente l’antigene ovalbumina (OVA).  Allo 
scopo di chiarire il ruolo dell’ossido nitrico nell’immunoterapia cellulare adottiva, 
si è rivelato fondamentale la messa a punto di valide metodiche per monitorare il 
rilascio di questo radicale in tempo reale attraverso la microscopia confocale, che 
è stata condotta su “fettine” vitali di tumore in seguito all’interazione con le 
cellule T e l’isolamento tramite delle cellule responsabili dell’induzione di ossido 
nitrico dopo l’immunoterapia cellulare adottiva. 
Il nostro lavoro introduce un approccio innovativo per lo studio delle dinamiche 
dell’NO nel microambiente tumorale. Tale approccio è stato fondamentale per 
l’identificazione, per la prima volta nei tumori, di una nuova sottopopolazione 
mieloide, denominata “cellule dendritiche TNF/iNOS producenti” (Tip-DCs), 
caratterizzate da attività antitumorale che è mediata da NOS2 e conseguente 
produzione di ossido nitrico. Principalmente il nostro studio porta la 
consapevolezza che la NOS2 è fondamentale per l’efficacia dell’ACT, aprendo 
nuove prospettive per il miglioramento dell’immunoterapia del cancro basata sulla 
modulazione di NOS2 e dell’ossido nitrico nei tumori. 
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Introduction 
 
Despite considerable progress in the last decades, cancer still represent one 
leading cause of death in modern society. In the last 20 years, the survival of 
cancer patients with conventional treatment remains around at 10%. This poor 
clinical outcome highlights the need for new therapeutic approaches, providing 
long-lasting protection against disease recurrence. One promising branch is 
represented by cancer immunotherapy, based on the activation of the host immune 
system against tumors.  
Cancer immunotherapy encompasses different approaches as monoclonal 
antibody therapy, vaccines and adoptive cell therapy (ACT). Recent evidence 
suggests that the effectiveness of these new approaches relies on the capability of 
immune system to overcome the immunosuppressive tumor microenvironment. 
Since the cross-talk between immune cells and tumor mass is fundamental for the 
therapeutic outcome, the clarification of mechanisms that blocks immune system 
may represent a promising opportunity to improve the effectiveness of 
immunotherapies. 
 
1. Cancer immunotherapy 
The relationship between the immune system and human cancer is dynamic and 
complex. Individual human tumors harbour a multitude of somatic gene mutations 
and epigenetically dysregulated genes, which products could be potentially 
recognizable as foreign antigens (Segal et al., 2008). However, during tumor 
progression, immune cells establish a tolerance, where foreign molecules 
expressed by cancer cells are viewed as self (Schreiber et al., 2011). Cancer 
immunotherapy exploits distinct approaches as monoclonal antibody-based 
treatment, vaccines and ACT, to specifically activate both adoptive and innate 
responses against tumors. Here, we will briefly describe the first two approaches, 
mainly focusing on ACT, which will be the object of our study.  
 
1.1 Monoclonal Antibody-based therapy and Cancer Vaccines 
 Monoclonal antibodies (mAbs) are currently used in clinical oncology for 
the treatment of hematologic and solid tumors (Topalian et al., 2011). The 
mechanisms of tumor cell killing by antibodies can be classified in three groups: 
i) direct tumor cell killing, ii) immune-mediated tumor cell killing and iii) 
vascular and stromal ablation. In the first group, tumor killing could be elicited by 
the activation or inactivation of a specific receptor on tumor cells leading to 
apoptosis; antibodies can also bind enzymes leading to neutralization, signaling 
abrogation and cell death (Scott, Wolchok, and Old 2012). Direct killing also 
include antibodies loaded with cytotoxic agents as drug, small interfering RNA or 
radioisotope. In the second group the tumor killing can be the result of 
phagocytosis, complement activation cytotoxicity (CDC), antibody-dependent 
cellular cytotoxicity (ADCC), target of T cell genetically modified, T cell 
activation mediated cross-presentation of antigen to dendritic cells and inhibition 
of T cell receptor inhibitory. 
The third group is composed by antagonists or ligands trapping of vasculature’s 
receptors, stromal cell inhibitors and of course the antibodies which deliver toxins 
to stromal cells (Scott et al., 2012).  
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Tumor cell killing trough CDC and ADCC is based on Fc function of antibodies 
as mediator; in fact, it was shown that patients with high affinity to Fc receptor 
had better response than patients with low affinity in treatment of lymphoma with 
rituximab, which is based on ADCC (Weng and Levy, 2003). Others approaches 
have been successfully applied in the clinic by many new drugs: the abrogation of 
tumor cell signaling (for example, by cetuximab and trastuzumab) (Hudis, 2007; 
Van Cutsem et al., 2009), and the immune modulation of T cell function (for 
example, by ipilimumab) (Hodi et al., 2010).  
 Although promising results from different trials, treating malignant patients with 
antibodies may not achieve an adequate therapeutic effect for the heterogeneity of 
target antigen expression in tumors, which can be present initially or can develop 
during therapy. 
Therapeutic vaccines represent a valuable option for active 
immunotherapy of cancers (Guo et al., 2013). This approach induces or increases 
antitumor responses with optimal combinations of antigens, adjuvants and 
delivery vehicles (Melero et al., 2014). The mechanism required to mount an 
effective anti-tumor immunity is a multistep process. In the first step, tumor-
associated antigens (TAAs) must be directly presented by tumor cells or captured, 
processed and presented by dendritic cells. The second step requires the efficient 
activation and/or maturation of specific signals that allow dendritic cells to 
differentiate, migrate to the lymph nodes, and present TAAs to naive T 
lymphocytes. The third step involves the expansion of T cells in sufficient 
numbers to recognize and eliminate tumor cells. However, in the absence of 
suitable maturation signals, antigen presentation leads to T-cell anergy or 
generation of regulatory T cells (Treg) that suppress effector T cells. Finally, 
antigen-educated T cells must leave the lymph node, traffic to infiltrate the tumor 
and persist for long enough to kill the malignant cells (Mellman et al., 2011).  
Cancer vaccines can be classified as preventive or therapeutic. Preventive 
vaccines are administered to healthy subjects before tumor occurrence. They 
specifically aim to prime the host immune system, eventually eliciting long-term 
memory responses. Optimal results in cancer prevention were achieved with 
vaccine against hepatitis B virus (HBV), which prevents liver carcinomas in 
patients chronically infected by the virus (Finn, 2003). Moreover, The U.S. Food 
and Drug Administration (FDA) has approved two preventive vaccines for human 
papilloma virus Gardasil (HPV16) and Cervarix (HPV18), that protect against 
infection by the two types of HPV that cause approximately 70% of all cases of 
cervical cancer in worldwide (Doorbar, 2006). 
On the other hand, therapeutic cancer vaccines are designed to eradicate cancer 
cells at late stage disease by boosting patient'own immune responses (Lollini et 
al., 2006). Therapeutic cancer vaccines, which have been used in many clinical 
trials approved by FDA, encompass different mechanisms. Some examples 
include the following:  i) the use of antigen-presenting cells (APCs) derived from 
patient peripheral blood, incubated with recombinant fusion protein protein, 
consisting of prostatic acid phosphatase (PAP) linked with growth factors as 
granulocyte macrophage colony stimulating factor (GM-CSF) and infused back 
into the patient (Kantoff et al., 2010a); ii) recombinant viral vectors 
(PROSTVAC®-VF) (Kantoff et al., 2010b); iii) long-peptides for human 
papillomavirus and peptides in combination with immunostimulatory agents as 
GM-CSF (Hiltonol™ for breast cancer) (Mittendorf et al., 2012). These studies 
shown increase effectiveness in prolong survival patients with combinatorial 
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approaches; they also underline the need to establish the right quantities of 
antigens, the appropriate activation signals and delivery vehicles. Finally, cancer 
vaccines must break tolerance to reactive antitumor immune cells, highlighting 
the need of developing effective strategies for overcoming tumor-associated 
immunosuppression.  
In addition to the aforementioned vaccines, there are many clinical trials 
financially supported by National Cancer Institute, which are available at this 
link: http://www.cancer.gov/about-cancer/treatment/clinical-trials/search. 
 
1.2 Adoptive cell therapy (ACT)  
The adoptive cell therapy (ACT) is a promising approach for cancer treatment in 
which antitumor T cells are isolated from patients, manipulated ex vivo and finally 
re-infused into the patient. The technique harnesses the power of the immune 
system by activating host’s own T cells, which recognize and attack foreign 
invaders and diseased cells (Humphries, 2013).  During their life, T cells move 
throughout tissues, scanning for MHC–peptide complexes that specifically 
activate their T cell receptors (TCRs). Tumor-specific T cells are activated 
through encounters with tumor-associated antigens that are presented by 
specialized APCs, including dendritic cells (DCs), which process antigens and 
present them to T cells in the context of MHC class II molecules or in the context 
of MHC class I molecules trough a mechanism known as cross-priming. 
Theoretically, activated T cells are capable of directly recognizing antigens that 
are presented on the surface of many types of tumor cells in the context of MHC 
class I (either naturally or as a result of gene engineering) (DuPage et al., 2012; 
Restifo et al., 1993; Schreiber et al., 2011). However, neoplastic cells are 
notoriously unstable targets, which often downregulate the expression of MHC 
class I molecules. Notably, one of the major limitations of ACT is the lacking of 
TAA recognition from T cells infused on patients (Restifo et al., 2012). 
Additionally, an important factor limiting the successful use of ACT in humans is 
the identification of cells that can recognize antigens selectively expressed on 
cancer cells and not on non-malignant tissues (Rosenberg and Restifo, 2015)  
ACT encompasses different strategies based on either natural host cells that 
exhibit antitumor reactivity, or host cells that have been genetically engineered 
with antitumor T cell receptors (TCRs) or chimeric antigen receptors (CARs). 
Essentially, the ACT protocol consists in the isolation of tumor infiltrating 
lymphocyte (TIL), primed to attack tumor; and cultured in vitro with the T cell 
growth factor interleukin 2 (IL-2). Finally cells are infused back to the patients in 
association with IL-2 administration. Before to the adoptive transfer, hosts can be 
immunodepleted from endogenous immune system trough chemotherapy alone or 
in combination with total-body irradiation ensuring the cytotoxic activity of 
transferred T cells (Restifo et al., 2012). This strategy, dating back to 80’s, 
(Rosenberg et al., 1986) has been improved over the past years and today it 
represents the best available treatment for patients with metastatic melanoma 
(Besser et al., 2010; Dudley et al., 2005). However, TILs therapy is still limited to 
patients with good performance status who are capable of withstanding the rigors 
of the lymphodepletion and IL-2-based treatments that are currently used. A 
recent study of 93 patients with stage IV melanoma described three sequential 
trials in which patients were treated with the adoptive transfer of autologous TILs, 
administered in conjunction with IL-2 following host conditioning regimens. 
Objective clinical response rates ranged from 49% to 72% assessed using 
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response evaluation criteria in solid tumors (RECIST). Although patients can 
sometimes benefit enormously from partial responses, every patient aspires to 
become cancer free. Importantly, 20 of the 93 patients (22%) achieved complete 
tumor regression, and 19 of these 20 (93%) have ongoing complete regression 
with a minimum follow up of 57 months (Rosenberg et al., 2011). Indeed, some 
of these patients have been alive and disease free for more than 8 years and are 
probably ‘cured’ of metastatic melanoma. The likelihood of achieving a complete 
response was similar regardless of prior therapy. Thus, ACT therapy with 
autologous TILs can mediate durable complete responses in patients with 
metastatic melanoma and has similar efficacy irrespective of prior treatment 
(Besser et al., 2010; Itzhaki et al., 2011; Rosenberg et al., 2011).  
Despite these successes, the reasons why some patients respond favorably to this 
treatment and others do not remain unknown. At present, some studies in mice 
and humans have explored different aspects as the target specificities of the 
transferred T cells, the nature of the surrounding microenvironment and how it 
can be targeted (including the use of increased-intensity lymphodepletion), and 
finally the differentiation states of the cells involved (Restifo et al., 2012).   
Scientists are working to optimize two different ACT approaches based on T cell 
receptor modification, one called T cell receptor (TCR) therapy and the other, 
more flexible, chimeric antigen receptor therapy (CAR) (Essand and Loskog, 
2013). The TCR therapy consists in generation of alternative T cell receptors 
using viral vectors for delivery of genes encoding the new TCR. T cells after TCR 
engineering could recognize specific tumor antigens and they can also express 
factors that allow their persistence in the body. This method showed good results 
in clinical trials for metastatic melanoma, colorectal cancer and synovial cancer 
(Robbins et al., 2011). Despite the promising results, the use of TCR therapy is 
limited by the need of genetically match of the new receptor with patients’ 
immune type. CAR therapy seems more adaptable for avoiding this constraint, 
using a gene that encodes artificial, antibody-like proteins that bind the antigens 
on the tumor cell’s surface without needing to match the patient’s immune type. 
CARs are composed of three pieces: an antibody that binds to a common cancer 
antigen; part of a receptor that activates the cell; and one or more stimulatory 
molecules that help the T cell proliferate and persist.  CARs after their insertion 
and expression on T cell, work as a switch, in fact when they matched with tumor 
antigen, immediately activate T cell into attack mode. Although the potential of 
CAR, their use is reported only in small clinical trials, where it was reported good 
results on treatment of B-cell leukaemias and lymphomas, focusing on CD19 
protein expression (Kochenderfer et al., 2010). Although the positive results 
derived from clinical trials of ACT, this field still needs to be improved before a 
massive use in clinical. First, it is necessary the development of specialized cell 
production facilities and staff trained in genetically modifying and growing the 
cells. Moreover, it is fundamental to modulate the strength of immune cells to 
direct the cytotoxic attack only to neoplastic cells avoiding normal tissues, which 
can express similar antigens. Until now it is not totally understood why only some 
patients take benefits of ACT.  
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Figure 1. Schematic representation of different types of adoptive cell transfer. TILs re-infusion (left); 
(centre) TCR therapy; (right) CAR therapy (Humphries, 2013) 
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2. Tumor microenvironment complexity  
In the last decade it became clearly that tumor mass is a complex structure 
composed not only by neoplastic cells, but also from different cell populations 
which sustain cancer growth. Tumor microenvironment emerges from a complex 
framework where different corrupted resident or purposely recruited cells exert 
conflicting functions establishing a peculiar cytokine milieu. The stromal 
components of tumor microenvironment can be classified into three general 
classes: angiogenic vascular cells, cancer-associated fibroblastic cells and 
infiltrating immune cells (Hanahan and Weinberg, 2011). Remarkably, the 
localization, the type and numbers of immune cells infiltrating tumors correlate 
with patterns and subsets of prognostic biomarkers, first observed in colorectal 
cancer (Nosho et al., 2010; Ogino et al., 2009) and later introduced in clinical as 
novel parameter, called “immunoscore”. This new index supports cancer staging 
and identifies patients with high-risk of tumor recurrence, also facilitate clinical 
decisions as the rational stratification of patients could have major benefit from 
adjuvant therapy. The “immunoscore” considering the immune cell density, 
calculated by numerical quantification of two lymphocyte populations, cytotoxic 
and memory T cells both at the tumor core and the invasive margin (Galon et al., 
2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Tumor heterogeneity.  The tumor microenviroment is composed by cancer cells interacting 
dynamically with immune inflammatory cells, endothelial cells, fibroblast cells and endothelial cells 
(Sherman et al., 2012)  
 
Vascular endothelial cells and their associated pericytes, are fundamental during 
neovascularization, in fact those cells can originate new vessel from existing ones 
after sensing of soluble factors as vascular endothelial growth factors (VEGFs), 
fibroblasts growth factors (FGFs), platelet-derived growth factors (PDGFs) and 
chemokines produced from malignant cells and also from inflammatory cells 
(Carmeliet and Jain, 2011). The new vessels create chaotic vasculature in the 
tumors, which is characterized by leakiness of the raises, which cause unevenness 
of blood flow, oxygenation, nutrients and drug distribution in the tumor 
microenviroment. These anarchic structure, increases hypoxia and facilitate 
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metastasis (Jain, 2005). Cancer associated fibroblasts (CAFs), are myofibroblasts 
differentiated from some precursors such as smooth muscle cells, myoepithelial 
cells, mesemchymal cells and endothelial cells. (Brittan et al., 2002; Spaeth et al., 
2009; Tomasek et al., 2002; Willis et al., 2006). CAFs, differently from normal 
fibroblasts, which typically suppress tumor formation show pro-tumorigenic 
properties, since they enhance tissue remodeling, by increasing expression of 
proteolytic enzymes, such as matrix metalloproteinases, and extracellular matrix 
deposition. Moreover CAFs secrete distinctive factors as the stromal cell-derived 
factor 1 (SDF1), VEGFs, PDGFs, and the hepatocyte growth factor (HGF), 
promoting immune cell recruitment at tumor site (Polanska and Orimo, 2013). 
Distinct immune cell subsets so far populate the crowded tumor environment. 
Tumor-infiltrating immune cells comprise cells belonging to both subsets the 
adaptive and the innate immune compartments. Obviously, numerous cytotoxic 
lymphocytes CD8+ T cells and helper CD4+ T cells infiltrate the tumor 
microenvironment at the invasive margin and the lymphoid organs, normally their 
presence is associated with good prognosis. Over T lymphocytes, it was also 
reported the presence of natural killer (NK) cells, γδ T cells and natural killer T 
cells (NKT) and segregated B cells organized as tertiary lymphoid structures 
(TLS) (Goc et al., 2014). The role of these structure also the innate lymphocytes 
still not clear in the tumor microenvironment, it seems their activity could switch 
from anti-tumor to pro-tumor depending con the cytokines released in the milieu 
(Gajewski et al., 2013). Furthermore, myeloid population infiltrating tumor 
microenvironment, with mostly pro-tumor activity, encompass both terminally 
differentiated cells, as DCs, macrophages and granulocytes, and immature 
myeloid cells, as MDSCs, which are generated from bone marrow as a 
consequence of a cancer-induced abnormal myelopoesis (Gabrilovich et al., 
2012).  As anticipate above, DCs recruited within tumor microenvironment favor 
tumor evasion as consequent of the down-regulated expression of the MHC class 
II and co-stimulatory molecules CD80 and CD86, they do not adequately 
stimulate an effective immune response against tumor cells (Gabrilovich, 2004). 
Macrophages in the tumor core, called tumor associated macrophages (TAMs), 
exhibit M2 phenotype, or alternatively activated macrophages, which is activated 
by IL-4, IL-10, IL-13 and glucorticoid hormones, are characterized by secretion of 
high levels of IL-10 and low levels of IL-12 and favoring tumor progression 
(Mantovani et al., 2002). In fact, TAMs, on the contrary of M1 or classically 
activated macrophages with tumoricidal activity, shown poor antigen presenting 
capacity, promote angiogenesis and lymphangiogenesis, sustain tissue 
remodeling, tumor invasion and metastasis, and suppress anti-tumoral adaptive 
immunity. The same picture for the tumor associated granulocytes, which are 
mostly neutrophils, which shift from anti-tumor N1, characterized by high 
expression of immunoactivating cytokines and chemokines, to pro-tumoral 
phenotype N2 following TGF-β exposure, which is frequently secreted by cancer 
cells (Fridlender et al., 2009).  
Finally, MDSCs, heterogeneous population that include direct progenitors of DCs, 
macrophages and granulocytes and exploit multiple redundant mechanisms to 
influence both innate and adaptive immune responses, which can be grouped in 
four classes. The first, MDSCs induce the activation and expansion of regulatory 
T cells (Treg) population by promoting antigen-specific natural Treg clonal 
expansion and naive CD4+ T cell conversion into induced Treg cells. The second 
is based on nutrients depletion required by lymphocytes, i.e. L-cysteine 
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sequestration and L-arginine depletion through arginase1 (ARG1) dependent 
consumption, which cause TCR ζ-chain down-regulation and the proliferative 
arrest of antigen-activated T cells. The third interfering with lymphocyte 
trafficking and viability, by expressing at the plasma membrane ADAM17 
(disintegrin and metalloproteinase domain-containing protein 17), which cleaves 
key proteins for T cell recirculation to lymph nodes, and galectin-9 (GAL-9), 
which induce T cell apoptosis. Finally, the fourth sustain oxidative stress within 
production of reactive oxygen species (ROS), nitric oxide (NO) and other reactive 
nitrogen species (RNS), by the synergistic activity of ARG1, iNOS and NADPH 
oxydase enzymes in the tumor microenvironment (Gabrilovich et al., 2012). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Mechanisms of MDSC-dependent inhibition of T cell activation and proliferation. Myeloid-
derived suppressor cells (MDSCs) can inhibit efficient antitumour T cell responses through a number of 
mechanisms. a) Tumour-associated MDSCs induce the development of regulatory T (Treg) cells or expand 
existing Treg cell populations. b) Tumour-associated myeloid cells deprive T cells of amino acids that are 
essential for their growth and differentiation. c) Tumour-associated myeloid cells release oxidizing 
molecules, such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO–) which cause nitration and 
nitrosylation of components of the T cell receptor (TCR) signalling complex, and the loss of the TCR ζ-chain, 
thereby inhibiting T cell activation through the TCR. d) Tumour-associated myeloid cells can also interfere 
with T cell migration and viability through ADAM17 and GAL9 expression. 
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3. Nitric oxide production in biological systems 
NO is a stable colorless gas under atmospheric condition, which freely crosses 
cell membranes, blood and tissues with solubility and diffusion similar to oxygen; 
those characteristics are ascribed to the size (30 Da) and the absence of charge 
(Alderton et al., 2001). NO is involved in many different physiological and 
pathological conditions depending on its synthesis and concentration (Moncada et 
al., 1991). In biological systems, NO is generated enzymatically from L-arginine 
by NO synthase enzymes (NOS), according to the following chemical reaction: 
 
 
This reaction is catalysed by three different types of NOS enzymes, with 51-57% 
homology between the human isoforms, suggesting the existence of a common 
ancestral NOS gene: neural (nNOS or NOS1), inducible (iNOS or NOS2) and 
endothelial (eNOS or NOS3). NOS enzymes have similar genomic organization 
although, they are encoded by different genes with different localization, 
regulation, catalytic properties and inhibitor sensitivity. The nNOS gene is 
localized in a single position on human chromosome 12 and containing an intron 
gene at least of 20 kb (Hall et al., 1994).  The eNOS gene is located on 
chromosome 7 whereas the iNOS gene is mapped to chromosome 17 (Janssens et 
al., 1992). Although different locations on human chromosomes, the NOS 
enzymes show similar structure composed by bidomains: an NH2-terminal 
catalytic oxygenase domain that binds heme (i) iron protoporphyrin IX), 
tetrahydrobiopterin (BH4), and the substratel-Arg; (ii) a COOH-terminal reductase 
domain that binds flavin mononucleotide (FMN), flavin adenine dinucleotide 
(FAD), and NADPH; and (iii) an intervening calmodulin-binding region (Habib 
and Ali, 2011). Calmodulin increases the rate of electron transfer from NADPH to 
the reductase domain and triggers electron transfer from the reductase domain to 
the haeme centre (Matsuda and Iyanagi, 1999); it also is involved in the formation 
of a homodimer,  followed by intracellular Ca2+ variation,  resulting in enzyme 
activation. Calcium acts as a modulator especially for NOS1 and NOS3, which 
require higher amount for their activity than NOS2 (Tengan et al., 2012)  
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INTRODUCTION
Nitric oxide (NO) is a diffusible molecule, which is 
involved in many different physiological and pathological 
conditions. It modulates blood flow[1,2], neural activity[3] 
and immune defence mechanism[4]. 
In biological system , NO is mainly synthe ised enzy-
matically starting from L-argine according to th  following 
chemical reaction:
This reaction is catalysed by three different 
enzymes, identified in the ‘90s, ncoded by differ nt 
genes with differen  localization, regulation, catalytic 
properties and inhibitor sensitivity, called respectively 
neuronal (nNOS or NOS1), inducible (iNOS or NOS2) 
and endothelial (eNOS or NOS3) nitric oxide synthase. 
Genomic organization is similar among these isoforms 
suggesting a common ancestral progenitor and is composed 
by a bidomains structure (an oxigenase domain at N-term 
and  reductase one at C-term) with a intervening calmodulin 
(CaM) binding region between the two[5]. Cal odulin is 
necessary for the activity of all these enzymes, even though 
Ca2+-dependence of NO synthesis distinguishes the NOS 
isoforms, with nNOS and eNOS having a much higher Ca2+ 
requirement than iNOS. 
nNOS and eNOS are constitutively expressed among 
several cell types, including the endothelium, platelets, 
and neurons. Their function is mainly dependent on n 
intracellular calciu  rise, even though other calcium 
independent mechanisms could impact on it, for example 
shear stress[6-10]. 
On the other hand iNOS is largely expressed only 
after induction by immunologic and inflammatory stimuli 
and its role in the direct protection against pathogens has 
been clearly de onstrated. For example, the requirement 
of iNOS for the eradication of Mycobacterium tuberculosis 
infection has been established[11] as well for other 
Listeria monocytogenes[12] and the protozoan parasite 
Leishmania major[13,14] in the '90s. Recent evidence has 
contributed to clarify mechanisms upon this immune 
response[15-17].
A fourth enzyme has been more recently characterised 
in rat liver and named mithocontrial NO synthase or 
mtNOS[18,19]. This latter enzyme has been shown to be 
constitutively active, calcium dependent and ascribable 
for mitochondria homeostasis and bioenergetics. Indeed, 
it has been shown mainly by the group of Ghafourifar 
that activation of mtNOS upon chemotherapeutic drug 
administration induces oxidative and nitrative stress, with 
consequent apoptosis of cells[20,21].
NO is not only the product of NOS enzymes but it 
is also generated in tissues by either direct dispro-
portionation or reduction of nitrite to NO under the 
acidic and highly reduced conditions occurring in 
disease states, such as ischemia[22-24]. The biological 
significa ce of this alternative source of NO production 
consists in r storing p ysiological NO level when 
enzymatic production is uncoupled or dysregulated, as 
in atherosclerosis[25] or other inflammatory status[26].
NO AND RNS
Unlike reactive oxygen species (ROS), which are directed 
into the phagosome, NO is synthesised in the cytoplasm of 
the cell and diffuse rapidly across cell membrane[4]. Due to 
its chemical characteristics, NO could rapidly react with other 
free radicals such as O2-• to generate the highly reactive 
oxidant peroxinitrite (ONOO-) and other reactive nitrogen 
species (RNS), which have been intriguingly associated with 
many pathological conditions such as chronic inflammation, 
atherosclerosis[27], diabetes[28], inflammatory bowel 
disease[29] and autoimmune diseases[30]. Peroxynitrite has 
multiple cytotoxic effects which are ascribable to aberrant 
generation of proteins, post-translational modification 
(PTMs) of the existing ones, DNA damage, activation 
of poly(ADP-ribose), mitochondrial dysfunction and cell 
death thus widely affecting transcriptional regulation, gene 
expression and cell signalling[31,32]. 
Among the several RNS-induced modifications, the 
prevalent reaction is the coupling of a NO moiety with 
sulfhydryl groups on proteins, yielding S-nitrosothiols. The 
most affected residue is tyrosine. Nowadays, the presence 
of nitro-tyrosine is commonly accepted as a hallmark of 
in situ inflammation and is associated with many different 
pathologies, spacing from atherosclerosis, genetic disorders 
to cancer[33-36]. However, NO alone is not capable of 
nitrating tyrosine thus the accumulation of 3-nitrotyrosine 
is the reaction product of the other RNS[37]. Moreover, 
under inflammatory conditions, tyrosine nitration may be 
dependent on the activity of myeloperoxidase, secreted by 
monocytes and polymorphonucl ar neutrophils[38].
The biological significance of such modified residues 
lied in altered protein degradation[39], modification in 
protein properties[40,41], resulting signalling[42] and many 
other phenomena[43].
Tyrosine is not the only amino acid that is affected 
by the presence of RNS. Indeed, most of the amino 
acids containing aromatic rings could react with RNS and 
ROS. Among these, modifications of tryptophan were 
highlighted. Initially, nitration of tryptophan residues in 
proteins was assessed by means of proteomic assays, 
such as decreased in tryptophan-associated fluorescence 
and mass spectrometry, and was associated with 
decreased functionality of modified proteins[44]. However, 
the majority of the studies so far was unable to detect 
nitro-tryptophan derivatives in vivo due to the lack of 
good antibodies. This gap was recently filled by Ikeda 
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Figure 4. Schematic diagram illustrating domains and structure of human NOS enzymes. (a) Schematic 
representation of the diametric conformation of nitric oxide synthases (NOS) with both subunits attached at 
the oxygenase domains (green); (b) Domains structures of differences of three isoforms nNOS, eNOS and 
iNOS of NOS isoforms. PDZ domain is typically present in neuronal NOS (nNOS), the presence of 
myristoylation (Myr) and palmitoylation (Palm) sites are specific to endothelial NOS (eNOS). All isoforms 
the oxygenase domain contains binding sites for l-arginine (Arg), Heme and tetrahydrobiopterin (BH4), 
calmodulin (CAM), the reductase domain binds FMN, FAD and NADPH (Tengan et al., 2012).  
 
nNOS and eNOS, also referred as constitutive NOS (cNOS), are constitutively 
expressed among several cell types, including the vascular endothelium cells, 
platelets, and neurons.  The cNOS in response to physiological stimuli that trigger 
intracellular Ca2+ rise produce low levels of NO rapidly and transiently.  Low- 
levels of NO produce rapid transient cellular response as like modulate neural 
activity, blood flow, smooth-muscle relaxation. On the contrary the inducible 
NOS is not express on resting cells but it is induced by immunologic and 
inflammatory stimuli such as endotoxin (lipopolysaccharide, LPS) or cytokines as 
interferon gamma (INF-γ), interleukin-1 (IL-1) and tumor necrosis factor alpha 
(TNF-α) (Alderton et al., 2001). After a lag period necessary for protein synthesis 
iNOS produce high amount of NO, which acts directly with cytotoxic effect 
against pathogens as like Mycobacterium, Listeria monocytogenes and 
Leishmania maijor. Finally, recent studies reported another enzyme as NO 
producer, named mithocondrial NO synthase (mtNOS). This enzyme activity 
calcium dependent is fundamental to mitochondria homeostasis, was described 
firstly at rat liver, where it is constituvely active (Ghafourifar and Cadenas, 2005).  
 
3.1 Nitric Oxide direct biological effects: focus on immune system 
Nitric oxide, at low concentration as omnipresent intercellular messenger, 
regulates many physiological processes as blood flow (Wolin, 2009), and 
neurotransmission (Steinert et al., 2011). These functions are classified as direct 
effects of NO, which is mainly produced by the cNOS enzymes (NOS1 and 
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synthesis: tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), flavin monucleotide (FMN) 
and nicotinamide adenine dinucleotide phosphate (NADPH) [3]. 
Although all three NOS isoforms are products of different genes, they have similar structure with 
50%–60% sequence identity [7] and are only active as dimer [10] (Figure 1). Each subunit of this 
dimeric complex is composed by two domains, oxygenase and reductase domains. The oxygenase 
domain contains the binding sites for L-arginine, BH4 and heme (Fe) and the reductase domain binds 
to FMN, FAD, NADPH and calmodulin [7,10,11]. Both subunits are attached at the oxygenase 
domain, forming the dimeric conformation. In skeletal muscle, the nNOS isoform has an additional 
250 amino acid N-terminal sequence, the PDZ motif, that target the enzyme to the sarcolemma, in 
skeletal muscle [7]. Myristoylation and palmitoylation sites are typically present in eNOS N-terminal. 
Acylation by myristate and palmitate is required for the subcellular localization of eNOS in the 
caveolae of endothelial cells [11]. 
Figure 1. Schematic diagram illustrating the organization of human nitric oxide synthases. 
(a) Schematic figure showing the dimeric conformation of nitric oxide synthases (NOS) 
with both subunits attached at the oxygenase domains (green); (b) Main structure 
differences between the three types of NOS isoforms. PDZ domain is typically present in 
neuronal NOS (nNOS), the presence of myristoylation (Myr) and palmitoylation (Palm) 
sites are specific to endothelial NOS (eNOS). All isoforms the oxygenase domain contains 
binding sites for L-arginine (Arg), Heme and tetrahydrobiopterin (BH4) while the reductase 
domain binds to calmodulin (CAM), FMN, FAD and NADPH. iNOS = induced NOS. 
 
Since the first isolation and characterization of NOS [12], several splice variants have been 
discovered [13,14]. nNOS is encoded by the gene NOS1 localized in chromosome 12q24.22, contains 
29 exons and has at least te  transcript variants [15]. The classical isoform (nNOSα) is predominantly 
found in neuronal cells, contains both exon 2, which is responsible for the catalytic activity of the 
enzyme and the PDZ domain, which interacts with membrane proteins [16]. nNOSβ and nNOSδ lack 
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NOS3) associated with the intracellular calcium concentration. In addition, NO 
plays fundamental role in immune system especially for antiviral and 
antimicrobial activities, both cytotoxic (tissue-damaging) and cytoprotective 
(tissue-preserving), acting as either an immune-stimulatory (pro-inflammatory) or 
immunosuppressive (anti-inflammatory) agent (Predonzani et al., 2015). Most of 
NO production in immune cells derived from iNOS enzyme activity in 
macrophages or other host cells, which also provokes the depletion of local 
arginine (together with ARG1) sustaining growth inhibition and death of the 
parasites.   
Since NO activity depends on its local spatio-temporal concentration, the 
phenotype and functional commitment of the immune cells, responsible for its 
generation, dramatically impact on its own activity. Generally, macrophages after 
cytokines or microbial stimulation, sustain cytostatic or cytotoxic activity, through 
iNOS expression, against pathogens and tumor cells (Farias-Eisner et al., 1994; 
MacMicking et al., 1997). Historically, macrophages were classified into two 
major categories (M1/M2) depending on their activation status and inflammatory 
attitude. Once differentiated, M1 or classically activated macrophages trigger Th1 
immune response and secrete high amounts of NO to kill intracellular pathogens 
and to exert cytotoxicity towards tumor cells (Sica and Mantovani, 2012). On the 
other side, M2 macrophages express high levels of ARG1, which competes with 
iNOS for their common substrate L-arginine, thus preventing NO generation. This 
paradigm underlines that NO represents a remarkable hallmark of macrophages 
activation in pathological settings as infection or cancer, where they may exert 
divergent roles (Biswas and Mantovani, 2010; Murray et al., 2014). Considering 
macrophages plasticity, it has been proposed that in the early stages of tumor 
progression, macrophages exploit high concentrations of NO and RNS to kill 
tumor cell clones. Later on, macrophages corrupted by tumor microenvironment 
produce low levels of NO/RNS, which in turn promote cancer growth and 
spreading. The dichotomous activity of macrophage-derived NO definitely 
mirrors their functional plasticity in response to environmental cues. The 
multifaceted role of NO in cancer biology will be discuss below in the proper 
paragraph of this text named “The intricate role of nitric oxide in cancer biology.”  
Beyond macrophages, there are alternatives sources of NO in immune system 
(Coleman, 2001).  
Interestingly, recent works described a new subset of dendritic cells, able to 
produce nitric oxide trough iNOS expression, named TNF/iNOS (Tip) producing 
dendritic cells (Tip-DCs). Until these recent reports the role of DCs as potential 
NO-producing cells were debated and so far it has not been fully investigated the 
expression of iNOS as well as NO production participate in the innate defence 
against intracellular pathogens (Serbina et al., 2003).  
 
3.2  TNF/iNOS producing dendritic cells: new source of nitric oxide. 
Inflammatory immune responses against tumors and invading pathogens require 
the recruitment of immune cells to the site of damages. In this context, a key role 
is played by DCs, which are considered the most powerful antigen presenting 
cells, representing the bridge between innate and adaptive immunity (Katsnelson, 
2006). In the canonical maturation pathway, microbial products trigger DC 
activation, which leads to the production of large amounts of cytokines, especially 
interleukin-12 (IL-12) and IFN-α, driving the differentiation of naive T-cells into 
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effector cells (Smith-Garvin et al., 2009). Moreover, DCs exposed to 
inflammatory cytokines rapidly activate other innate protective cells such as NK 
and NKT cells (Fernandez et al., 1999).   
Based on distinct surface markers (Table 1), DCs are phenotypically divided in 
different cell subpopulations: i) conventional DCs (cDCs) derived from common 
DC progenitors (CDP) which are divided in two main categories migratory DCs  
and lymphoid tissue-resident DCs; ii) alternatively DC differentiated from 
monocyte intermediate precursors and finally iii) non-conventional plasmacytoid 
DCs (pDCs) (Belz and Nutt, 2012).  
 
  
Table 1. Phenotypic markers of DCs.!
 
Recently, as anticipate above, Serbina and colleagues described a novel subset of 
dendritic cells, Tip-DCs. In this work performed with a mouse models of L. 
monocytogenes infections, it was observed a population defined by these surface 
markers as CD11bint CD11cint Gr-1+ DEC-205− CD14− F4/80− associated with 
morphology like-DC and also no adherence. Additionally to the co-stimulatory 
markers, these cells resulted able to prime T cells and also to produce NO and 
TNF-α. These features forge the name as TNF/iNOS producing dendritic cells. In 
this study, the authors described the antimicrobial activity of Tip-DCs, which 
were recruited in the infection site by the CCR2-signalling. Moreover, Tip-DCs 
(CD11b+Ly6C+CD11c+) were also described in Trypanosoma brucei infection 
model, where they exerted cytotoxic effects in the liver during the infection 
(Bosschaerts et al., 2010). In this model, CCR2+ inflammatory monocytic cells, 
derived from CD11b and Ly6C expressing cells, were described as probably 
precursor of liver Tip-DCs. In this experimental model, the differentiation to Tip-
DCs from immature DCs (CD11c+ but CD80/CD86/MHC-class IIlow) is 
independent of IFN-γ and MyD88 signaling, whereas IFN-γ stimulation is 
necessary for TNF and iNOS/NO production (Bosschaerts et al., 2010).  
Based on the facts mentioned above, it is reasonable to conclude that Tip-DCs 
may derive from CCR2+ Ly6Chigh (Serbina and Pamer, 2006) macrophage/DC 
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progenitor (MDP) cells and have the potential to produce TNF/NO after 
appropriate stimulation (Schmid et al., 2012). Moreover it is also known that bone 
marrow-derived DCs (CD11c+, CD11b+, F4/80−) are able to produce TNFα and 
iNOS after stimulation (Ritter et al., 2003; Munder et al., 1999). Thus, it is 
difficult to see the dissimilarity between TiP-DCs and other activated monocyte-
derived cells (Taylor et al., 2005; Hume, 2008). In other words, it cannot be 
excluded that Tip-DCs do not represent a distinct DC subset but rather belong to 
common monocyte-derived DC responding to their environment with TNF/NO 
production (Serbina et al., 2003).  In addition to evidences from murine models, 
Tip-DC were described also in humans but in this first study their origin is 
ascribed to blood-monocytes (Chong et al., 2011). Indeed, it is clear that 
additional studies are required to further characterize these cells their mechanisms 
of recruitment, functions and origins.   
 
3.3 The CD40/CD40L axis. 
DCs interact with T lymphocytes trough the major histocompatibility complex 
(MHC) proteins expressed on their surface, and co-stimulatory receptors as CD40. 
CD40 is a transmembrane glycoprotein surface receptor that is a member of the 
Tumor Necrosis Factor Receptor superfamily (TNFRSF), originally described on 
B cells.  (Caux et al., 1994; Pinchuk et al., 1994). Cd40 signalling plays a key role 
in DC maturation and activity; in particular it promotes the upregulation of MHC 
class II and co-stimulatory molecules CD80/CD86, thus making DCs more 
effective APCs(Caux et al., 1994; Sallusto and Lanzavecchia, 1994). The ligand 
for CD40, CD154 (also known as TRAP, T-BAM, CD40 Ligand or CD40L) is a 
integral type II membrane protein. Initially, CD40L was reported to be expressed 
principally on activated CD4+ T cells, thus providing T cell help to B cells 
(Banchereau et al., 1994). Additionally, CD40L expression on activated T cells 
provides co-stimulation for effector T cell functions (van Essen et al., 1995; 
Grewal et al., 1995) as well as it mediates proper ‘licensing’ of DCs and APCs to 
prime CD8+ T cells. (Kelleher and Beverley, 2001).  Behind the initial 
classification,, it has been reported that CD40 molecules is also expressed on bone 
marrow stroma or  tumor stromal cells (Beatty et al., 2011; Ma and Clark, 2009). 
CD40L is expressed primarily by activated T cells, as well as activated B cells 
and DCs but it can also be induced on monocytes, NK cells, mast cells, and 
basophils under inflammatory conditions (Ma and Clark, 2009). An interesting 
aspect to be considered is the CD40-CD40L-dependent bidirectional crosstalk that 
occurs between DCs and lymphocytes. Indeed, it was shown that CD40-CD40L 
interactions between T cell and DCs provides reciprocal effects that both regulate 
T cells and DCs (van Essen et al., 1995). While it is clear that CD40L 
crosslinking can signal T cells e.g., to produce IFN-γ (Grewal et al., 1996; 
Mackey et al., 1998), it is not clear how ligation of CD40L on B cells or DCs 
affects their functions. 
The CD40-CD40L axis plays a prominent role in tumor biology. Indeed, although 
normally induced by helper T cells, CD40 signaling on APCs can also be 
effectively triggered using agonistic antibodies or CD40L (Khong et al., 2012). 
This represents the rationale for CD40 agonist-based cancer immunotherapy. 
CD40 has been exploited as a target for the treatment of different cancers using 
either recombinant soluble CD40L (sCD40L) or agonistic therapeutic antibodies 
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(Abs) (Khong et al., 2012). CD40 mAb represent so far a new therapeutic option 
in cancer, which has the potential to generate anticancer immunity by various 
mechanisms. In an elegant study, it has been recently demonstrated that CD40 
agonists are able to induce T cell-dependent and independent tumor regression in 
patients with pancreatic cancer (Beatty et al., 2011). 
  !
3.4 The intricate role of nitric oxide in cancer biology 
 As mentioned before, NO plays multiple role in cancer biology.  Mostly of the 
NO effects in cancer are indirect actions caused by NO metabolites (Pacher et al., 
2007).  Specifically, NO in cancer may act as tumor promoter or inhibitor 
depending on several factors as: NOS isoforms expression, source of NO 
production, concentration and timing of NO exposure and finally the sensitivity of 
cells to this radical (Fukumura et al., 2006).  
At the tumor site, NO combines with other radicals, leading to RNS generation 
that sustains genomic instability and blocks antitumor immune responses. 
Basically, high concentrations of NO and RNS can arrest cell cycle or induce cell 
death, whereas low concentrations may protect cells from apoptosis. High levels 
of NO/RNS post-translationally modify death-related target proteins, as the death 
receptors of the TNFα superfamily (Leon et al., 2008). Moreover, high NO 
concentrations, oxidizing and/or deaminating the DNA bases, result in DNA 
breaks, DNA base modifications or DNA cross-links, which cause mutations that 
may either activate oncogenes or deactivate tumor suppressor genes. In addition, 
NO/RNS-driven protein modifications such as S-nitrosylation or nitration may 
inhibit proteins belonging to the DNA repair systems, driving to genomic 
instability  
 Low concentration of NO sustains angiogenesis and metastasis. NO orchestrates 
angiogenesis, by maintaining the blood flow and vessel dilation during cancer 
development.  NO also induces vascular endothelial cell proliferation and 
migration trough the release of VEGFs which are fundamental for metastasis 
(Franchi et al., 2006; Fukumura et al., 2006). NO may also inhibit the aggregation 
of platelets through a cGMP-dependent mechanism, preventing aggregates 
formation with tumour cells, which may facilitate their adhesion to vascular 
endothelial cells and haematogeneous dissemination (Ogino et al., 2009). 
As previously mentioned, NO/RNS can suppress tumour-specific adaptive 
immunity through several mechanisms. The suppression of antitumor immune 
activity within the tumor microenvironment is induced in several ways. One is the 
arrest of adaptive immunity, induced either by inhibition of phosphorylation, or 
the activation of important signaling proteins in the IL-2-receptor pathway 
including Janus activated kinase 1 (JAK1), JAK3, STAT5, extracellular-signal-
regulated kinase (ERK) and AKT in T cells (Bingisser et al., 1998). Another 
mechanism of NO/RNS immunosuppression is the post-translational 
modifications of key proteins for T cell activation such as CD8 and TCR complex 
α/β chains molecules (Nagaraj et al., 2007), and the impairment of T lymphocyte 
recruitment to the tumor site, due to the posttranslational modification of the 
CCL2 chemokine (Molon et al., 2011). 
 On the other hand, NO plays also antitumor activity mostly exerted 
directly by high levels of NO, which can be summarized as cell cycle arrest 
(cytostatic effect) and cell death induction. The cytostatic effect based on the 
production of high levels of NO, and consequent RNS is the major weapon in the 
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macrophage’s arsenal against pathogens and tumor cells (Weigert and Brüne, 
2008). In addition, NO may induce apoptosis either via downregulation of the anti 
apoptotic protein survivin, as observed in human lung carcinoma cells (Chao et 
al., 2004), or upregulation of Fas expression, as shown in ovarian carcinoma cell 
lines, through the specific inactivation of the transcription repressor yin-yang-1, 
which binds to the silencer region of the Fas promoter (Bonavida, 2010). 
Finally, another way to induce apoptosis is the post-translational modification 
induced by high levels of NO/RNS of death-related target proteins, as the death 
receptors of the TNFα superfamily, and block respiration in target cells by 
affecting the mitochondrial respiratory chain and its outer membrane permeability 
and thus leading to the release of cytochrome c and apoptosis initiation (Leon et 
al., 2008)  
 
In addition to NO dichotomous role in tumor, some controversial evidence is also 
reported for NOS isoform localization, which is strictly correlated to cancer type.  
Certainly, NOS2 is the most expressed isoform in cancer and it is markedly 
expressed in approximately 60% of breast cancer, at 20% -25% respectively in 
colon adenomas and carcinoma. Moreover, NOS2 was also reported in other 
cancer types as head and neck, esophagus, lung, prostate, bladder and pancreatic 
carcinomas, brain tumors, Kaposi’s sarcoma, mesothelioma, and hematological 
malignancies. (Fukumura et al., 2006) In some cases NOS2 expression in the 
tumor cells was inversely correlated with tumor stage, grade and progression, and 
positively correlated with apoptosis and patient survival (Fukumura et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanisms of action of NO on tumor cells. NO can induce both pro-tumor effects at low 
concentration promote increase proliferation and angiogenesis, medium concentrations promotes increased 
invasiveness, metastasis increase cytoprotection and reduce apoptosis. At high concentration, promote DNA 
damages, oxidative/nitrative stress, cytotoxicity and apoptosis (Burke et al., 2013).   
  
Nitric oxide in cancer progression
metalloproteinases (MMP) are a family of ‘pro-metastatic’ enzymes 
involved in the degradation of b sement membrane proteins (69). 
A significant association was found between MMP-9 and NOS2 in 
hepatocellular carcinoma by immunohistochemistry, with MMP-9 
and NOS2 strongly correlating with risk of recurrence (70). NO 
donated by S-nitroso-N-acetyl-dl-penicillamine (SNAP) in colon 
adenocarcinoma cells increased MMP-2 and MMP-9 in a time-
dependent manner through activation of extracellular signal-regulated 
kinase (ERK)-1/2 and activating protein 1 (AP-1) (71). MMP-1, 
MMP-3, MMP-10 and MMP-13 were transcriptionally enhanced by 
NO in the human melanoma cell line C32TG. Further investigation 
showed that NO-mediated MMP-1 was activated through ERK and 
p38 mitogen-activated protein kinase pathways, which are highly 
activated during tumor inflammation, resulting in tumor progression 
(72). Additionally, NO activated epidermal growth factor receptor 
and Src signaling via S-nitrosylation in ER-negative and basal-like 
breast cancer, leading to activation of β-catenin signaling (73). DETA/
NO treatment led to decreased cell adhesion, decreased E-cadherin 
and concomitant increased expression of vimentin and β-catenin, 
indicating NO signaling results in ER-negative breast cancer EMT 
(73). The above studies demonstrate NOs ability to enhance tumor 
metastasis.
NO can also have anti-EMT effects. NOS2-transfected pancreatic 
cancer cells did not form tumors or metastases when injected into 
ectopic or orthotopic xenograft nude mouse models. Lack of tumo-
rigenesis was attributed to NO-mediated apoptosis (74). Cells from 
three NOS2 null tumor cell lines, KX-dw1, KX-dw4 and KX-dw7, 
were injected into NOS2+/+ and NOS2–/– mice. NOS2 null cells 
injected into NOS2–/– mice showed a higher proliferation rates and 
incidence of lung metastases than when transplanted into NOS2+/+ 
mice (75). Transforming growth factor-β1-induced EMT in alveo-
lar cells was reduced by treatment with NO donors (76). In another 
experiment, inhibition of NOS with l-NAME led to spontaneous 
EMT (76). Constitutively activated Snail, downstream of nuclear 
factor-kappaB (NF-κB), induces metastasis, whereas Raf-1 kinase 
inhibitor protein (RKIP) and E-cadherin repress metastasis. NO can 
inhibit Snail, thereby inducing RKIP, consequently inhibiting metas-
tasis (77). RKIP overexpression mimics NO in tumor cell-induced 
sensitization to apoptosis. In resistant tumor cells, there appears to 
be a dysregulated NF-κB/Snail/YinYang1(YY1)/RKIP circuitry (78). 
Prostate metastatic cell lines treated with high levels of DETA/NO 
show decreased Snail, increased RKIP and E-cadherin, thereby inhib-
iting EMT. Additionally, tumor cells were sensitized to apoptotic 
stimuli (77). Topical treatment of NO-exisulind ultraviolet B-induced 
skin tumors in a murine model reduced EMT with decreased fibronec-
tin, N-cadherin, SNAIL, Slug and Twist and increased E-cadherin 
(79). In contrast to the above studies, NO inhibited MMP-9 expres-
sion and activity in an orthotopic model of renal cell carcinoma (80). 
12-O-tetradecanoylphorbol 13-acetate-induced MMP-9 is inhibited in 
an NO-dependent manner in MCF-7 breast cancer cells (81). Also, 
NO can destabilize MMP-9 mRNA (82). In HCC 1806 triple negative 
breast cancer cells, NO was found to upregulate N-Myc downstream-
regulated gene 1 (NDRG1) in a dose- and time-dependent manner. 
NDRG1 expression in turn suppressed tumor cell migration (83).
Nitric oxide and angiogenesis
Angiogenesis is imperative for tumor progression, and NO is a 
key mediator of this process. Without the means to supply a tumor 
with nutrients and remove its waste products, tumor expansion 
and metastasis would be impossible. NO can promote or inhibit 
angiogenesis, depending on concentration and duration of exposure, 
intrinsic sensitivity of cells to NO and the activity and distribution of 
NO (23). NO acts as downstream mediator of multiple angiogenic 
effectors but its mechanisms are complex and involve multiple 
pathways (84). Angiogenic factors such as vascular endothelial 
growth factor (VEGF), sphingosine-1-phosphate, angiopoietins, 
estrogen, shear stress and metabolic stress stimulate the release of 
endothelium-derived NO by upregulation of NOS3 (85). Inhibition of 
NOS prevented prostaglandin E1-induced angiogenesis in the rabbit 
cornea in vivo, whereas angiogenesis was stimulated by NO-donor 
sodium nitroprusside (SNP) in these models (86). In vascular segments 
of rabbit thoracic aorta, VEGF stimulated a 2-fold NO release by 
pre-incubation with l-arginine (87). l-NAME blocked formation 
of capillary tubes induced by basic fibroblast growth factor and 
transforming growth factor-β on human umbilical venous endothelial 
cells in a 3-D gel, by terminating proliferative actions of growth 
factors and promoting differentiation of quiescent endothelial cells 
into vascular tubes (88). NO also exerts proangiogenic effects through 
inhibition of endogenous antiangiogenic factors. Thrombospondin 1 
was reduced in vascular endothelial cells by addition of an NO donor 
Fig. 1. Concentration-dependent effects of NO in cancer. Low levels of NO (<100 nM) promote increased proliferation and angiogenesis. Medium levels of NO 
(100–500 nM) promote increased invasiveness, metastasis, cytoprotection and repress apoptosis. High levels of NO (>500 nM) promote DNA damage, oxidative/
nitrosative stress, cytotoxicity and apoptosis.
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4. Methods to detect Nitric oxide production in biological systems 
Since NO is involved in many physiological and pathological conditions, the 
precise detection and quantification of this chemical mediator is pivotal to 
understand its activity in the different biological contexts. Due to the extremely 
short half-life of this free radical, its very low, in some cases subnanomolar, 
physiological concentrations and to its high reactivity toward oxygen and many 
other substances, NO measurement represents a technical challenge for scientists.  
A possible way to overcome the transient nature of NO in biological samples is to 
measure its stable metabolites, nitrate and nitrite. The quantification of NO 
metabolites in biological samples provides valuable information with regards to in 
vivo NO production, bioavailability and metabolism. Nonetheless, this approach 
does not provide information on instantaneous NO concentration or the rate of 
NO generation, which can be physiologically relevant. 
Indeed, methods continue to be developed and validated allowing the detection 
and quantification of NO and NO-related products/metabolites in multiple 
compartments of experimental animals (Bryan and Grisham, 2007). 
NO determination may be performed by either direct or indirect methods. Direct 
NO detection is based on the use of fluorimetric probes (Kojima et al., 1998) 
whereas indirect methods employ other approaches such as spectrophotometric 
measurements (Grisham et al., 1996). One spectrophotometric method is the 
Greiss reaction consisting of a two-step diazotization reaction in which the NO-
derived nitrosating agent, dinitrogen trioxide (N2O3) generated from the acid-
catalyzed formation of nitrous acid from nitrite (or autoxidation of NO) reacts 
with sulfanilamide to produce a diazonium ion which is then coupled to N-(1-
napthyl) ethylenediamine to form a chromophoric azo product that absorbs 
strongly at 540 nm (Grisham et al., 1996). Despite these method is only an 
indirect determination of NO production, it is useful for the easy quantification 
and also for the commercial available preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The Greiss reaction. The nitrosating agent dintrogen trioxide (N2O3) generated from acidified 
nitrite (or from the autoxidation of NO) reacts with sulfanilamide to yield a diazonium derivative. This 
reactive intermediate will interact with N-1-naphthylethelene diamine to yield a colored diazo product that 
absorbs strongly at 540 nm. (Bryan and Grisham, 2007) 
 
Another spectrophotometrical assay is the High Performance Liquid 
Chromatography (HPLC) Determination: a dedicated HPLC system developed by 
EiCom Corporation allows sensitive and selective measurement of nitrite and 
Figure 2. The Griess Reaction
The nitrosating agent dintrogen trioxide (N2O3) generated from acidified nitrite (or from the
autoxidation of NO) reacts with sulfanilamide to yield a diazonium derivative. This reactive
intermediate will nteract with N-1-naphthylethelene diamine to yield a colored diazo product
that absorbs strongly at 540 nm.
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nitrate in all biological matrices with ease and high throughput. The high 
sensitivity derived from the combination of HPLC with Greiss reaction for the 
detection.  
The fluorimetric methods, as fluorescence imaging, have many advantages in 
view of its sensitivity, selectivity, spatiotemporal resolution, and experimental 
feasibility. Thus, a variety of fluorescent probes have been developed since the 
1980s. The ideal fluorescent probes for NO bioimaging should have the following 
characteristics: water solubility, membrane permeability, non-cytotoxic, high 
sensibility and sensitivity for NO and its derivatives at low levels also for its 
variation, finally excitable at low-energy at low-energy wavelengths so that the 
induced auto-fluorescence can be effectively prevented (Li and Wan, 2015). 
Although some fluorescent probes were designed during the last years and they 
can be classified in two main groups organic-based and metal-based fluorescent 
probe, both became widely used in NO studies (Li and Wan, 2015). 
The organic-based fluorescent NO probes are mostly composed of two elements: 
a NO-reactive moiety and a fluorophore. The NO-reactive moiety act as a 
modulator in the photoinduced electron transfer (PeT) mechanism, which 
quenches the fluorescence of fluorophores until it binds with the NO or NO 
oxidized products (Hall and Garthwaite, 2009). This structure has been widely 
used to develop NO-responsive organic-based probes as DAF-FM and DAF-4M 
AM. Both probes contain o-diamine as functional groups. The electron-rich 
vicinal amines are thought to transfer energy to the aromatic group with PeT to 
quench the fluorescence. An o-diamine functionality reacts with an oxidized form 
of NO to produce an electron-poor fluorescent triazole derivative, which 
dissipates the PeT pathway and restores the fluorescence (Nagano and Yoshimura, 
2002). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Mecchanism of  florescence probes based on  o-diamine probes. The probes until reaction with 
NO is colorless, while the NO- binding induce fluorescence emission.  
 
DAF-FM is the result of an evolution of development of fluorescent o-diamine 
probes, in fact the first classes of fluorescent probes DAFs incorporate fluorescein 
with unstable fluorescence while DAF- FM was based on the increased resistance 
to photo-bleaching of fluorinated fluorescein derivatives. DAF-FM contains 
substituted fluorine atoms at the 2′ and 6′ positions and an N-methyl group, also a 
diacetate or acetoxymethyl ester moiety, which can be readily hydrolized by 
intracellular esterases, was introduced to make it membrane permeable (Kojima et 
al., 1998). Further the photo-bleaching DAF-FM resulted sensitive to ph variation, 
so the same group designed rhodamine B fluorophore-based probes named 
diaminorhodamines (DARs), comprising DAR- 4M AM.  Similar to DAF-FM, 
2 Organic-based ﬂuor scent
NO probes
Organic-based fluorescent NO probes often comprise of two
elements, a NO-reactive moiety and a fluorophore. The NO-
reactive moiety serves as a modulator in the photoinduced
electron transfer (PeT) mechanism, which quenches the fluo-
rescence of fluorophores until it reacts with the NO or NO oxi-
dized p oducts.13 The o-diamine functionality has be n widely
used to dev lop NO-respon ive organic-based probes.
2.1 Fluorescent probes based on o-diamine functionality
Nagano’s group first developed a series of molecules contain-
ing o-diamine functional groups.14 The electron-rich vicinal
amines are thought to transfer energy to the aromatic group
with PeT to quench the fluorescence. An o-diamine functional-
ity reacts with an oxidized f rm of NO to produce an electron-
poor fluorescent triazole deriv tive, which dissipate the PeT
pathway and restores the fluorescence (Fig. 1).
Based on the above principle, probes incorporating diami-
nofluoresceins (DAFs) were therefore designed, synthesized,
and applied to detect NO in living cells. The corresponding tri-
azole version of DAFs is DAF-Ts. Fig. 2 shows the chemical
structures of some representative DAFs and DAF-Ts.16,17
Among DAF analogs, DAF-2 has b en widely used for NO
imaging in living cells. Transformation of DAF-2 by NO results
in highly fluorescent DAF-2Ts, whose fluorescence quantum
eﬃciency is increased more than 180 times. A linear corre-
lation exists between the fluorescence response and the con-
centration of NO up to around 1000 nM with the detection
limit of less than 5 nM.16,17 DAF-4 and DAF-2 have similar
detection limits.
Among these DAF probes, DAF-2T exhibits remarkable
d crease in luorescence at pH values below 7, which is partly
because the pKa of the phenolic proton on DAF-2T is 6.27 ±
0.02. Thus, it is usually used at pH values above 7. DAF-4 and
DAF-5 are the dichloro derivatives of DAF, and two chlorine
atoms are introduced to reduce the pKa in DAF-4 and DAF-5.
The excitation and emission wavelengths of DAF-4 and DAF-5
are red-shifted because of the presence of a chlorine atom
adjacent to the phenolic hydroxyl group. However, DAF-4 and
DAF-5 are unexpectedly less useful than DAF-2 owing to their
unstable fluorescence around neutral pH. A new generation
DAF probe, DAF-FM, was developed based on the fact that
fluorinated fluorescein derivatives are more resistant to photo-
bleaching than fluorescein.18 DAF-FM contains substituted flu-
orine atoms at the 2′ and 6′ positions and an N-methyl group
(Fig. 3). The photobleaching of DAF-FM T is much less pro-
nounced than DAF-2T. For example, the fluorescence intensity
of DAF-FM T was reduced to 94% of the initial intensity after
exposure to sunlight for 1 h, while that of DAF-2T was
decreased to 58%. The fluorination lowers the pKa of the phe-
nolic hydroxyl group of DAF-FM to 4.38 ± 0.05. The spectra of
the NO adduct of DAF-FM are essentially independent of pH
above 5.5. The sensitivity of DAF-FM is 1.4 times higher than
that of DAF-2.18,19
To make the probes membrane-permeable, a diacetate or
acetoxymethyl ester moiety is introduced into the aforemen-
tioned molecules. The esters can be readily hydrolyzed by
intracellular esterases.18
Although DAFs are the first synthesized fluorescent NO
sensors, they are highly pH sensitive and have problems with
photobleaching. Hence, Nagano’s group subsequently
designed and synthesized rhodamine B fluorophore-based
probes named diaminorhodamines (DARs) (Fig. 4). The reac-
tion between DARs and NO yields the corresponding fluo-
rescent triazole, as in the case of DAFs. Among the DAR
family, DAR-4M was prepared from DAR-1 with one of the
amines replaced with methylamine. The fluorescence intensity
of the triazole form of DAR-4M does not exhibit a pH-depen-
dence at pH above 4. The fluorescence quantum eﬃciency is
Fig. 1 Mechanism of ﬂuorescent response of probes based on o-diamine
functionality.
Fig. 2 Structures of DAFs and DAF-Ts. Fig. 3 Structures of DAF-FM and DAF-FM DA.
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DAR-4M AM is the result of evolution of many probes designed earlier, anyway 
it structure contain one of the amines replaced with methylamine. DAR 4M AM 
show stable fluorescence, high sensitivity at low concentration of NO (7nM) and 
stability to intracellular ph variation (Itoh et al., 2000).  
 
 
Figure 8. Structures of o-diamine probes. Diamminofluoresceins probes from in (a) chemical structure of 
DAF-FM, in (b) DAF-FM DA, in (c) chemical structures of diamminorhodamine probes. 
 
Since both probes as DAF-FM as DAR-4M AM are commercially it is reported 
from several works their application to detect NO in biological experiments as the 
production in macrophages or in endothelial cells.  
Finally, the metal- transition based fluorescent probes, which structure contains a 
fluorescein modified with an appended metal-chelating ligand, the incorporated 
fluorophore can be quenched by intracellular photoinduced electron transfer and/ 
or coordination to a paramagnetic or heavy metal ion. These probes can form 
direct and reversible bond with nitric oxide, becoming the best choice for the 
detection in real time of NO production, while others probes recognize the 
oxidized form and establish irreversible bonds with NO (Lim, 2007). 
  
2 Organic-based ﬂuorescent
NO probes
Organic-based fluorescent NO probes often comprise of two
elements, a NO-reactive moiety and a fluorophore. The NO-
reactive moiety serves as a modulator in the photoinduced
electron transfer (PeT) mechanism, which quenches the fluo-
rescence of fluorophores until it reacts with the NO or NO oxi-
dized products.13 The o-diamine functionality has been widely
used to develop NO-responsive organic-based probes.
2.1 Fluorescent probes based on o-diamine functionality
Nagano’s group first developed a series of molecules contain-
ing o-diamine functional groups.14 The electron-rich vicinal
amines are thought to transfer energy to the aromatic group
with PeT to quench the fluorescence. An o-diamine functional-
ity reacts with an oxidized form of NO to produce an electron-
poor fluorescent triazole derivative, which dissipates the PeT
pathway and restores the fluorescence (Fig. 1).
Based on the above principle, probes incorporating diami-
nofluoresceins (DAFs) were therefore designed, synthesized,
and applied to detect NO in living cells. The corresponding tri-
azole version of DAFs is DAF-Ts. Fig. 2 shows the chemical
structures of some representative DAFs and DAF-Ts.16,17
Among DAF analogs, DAF-2 has been widely used for NO
imaging in living cells. Transformation of DAF-2 by NO results
in highly fluorescent DAF-2Ts, whose fluorescence quantum
eﬃciency is increased more than 180 times. A linear corre-
lation exists between the fluorescence response and the con-
centration of NO up to around 1000 nM with the detection
limit of less than 5 nM.16,17 DAF-4 and DAF-2 have similar
detection limits.
Among these DAF probes, DAF-2T exhibits remarkable
decrease in fluorescence at pH values below 7, which is partly
because the pKa of the phenolic proton on DAF-2T is 6.27 ±
0.02. Thus, it is usually used at pH values above 7. DAF-4 and
DAF-5 are the dichloro derivatives of DAF, and two chlorine
atoms are introduced to reduce the pKa in DAF-4 and DAF-5.
The excitation and emission wavelengths of DAF-4 and DAF-5
are red-shifted because of the presence of a chlorine atom
adjacent to the phenolic hydroxyl group. However, DAF-4 and
DAF-5 are unexpectedly less useful than DAF-2 owing to their
unstable fluorescence around neutral pH. A new generation
DAF probe, DAF-FM, was developed based on the fact that
fluorinated fluorescein derivatives are more resistant to photo-
bleaching than fluorescein.18 DAF-FM contains substituted flu-
orine atoms at the 2′ and 6′ positions and an N-methyl group
(Fig. 3). The photobleaching of DAF-FM T is much less pro-
nounced than DAF-2T. For example, the fluorescence intensity
of DAF-FM T was reduced to 94% of the initial intensity after
exposure to sunlight for 1 h, while that of DAF-2T was
decreased to 58%. The fluorination lowers the pKa of the phe-
nolic hydroxyl group of DAF-FM to 4.38 ± 0.05. The spectra of
the NO adduct of DAF-FM are essentially independent of pH
above 5.5. The sensitivity of DAF-FM is 1.4 times higher than
that of DAF-2.18,19
To make the probes membrane-permeable, a diacetate or
acetoxymethyl ester moiety is introduced into the aforemen-
tioned molecules. The esters can be readily hydrolyzed by
intracellular esterases.18
Although DAFs are the first synthesized fluorescent NO
sensors, they are highly pH sensitive and have problems with
photobleaching. Hence, Nagano’s group subsequently
designed and synthesized rhodamine B fluorophore-based
probes named diaminorhodamines (DARs) (Fig. 4). The reac-
tion between DARs and NO yields the corresponding fluo-
rescent triazole, as in the case of DAFs. Among the DAR
family, DAR-4M was prepared from DAR-1 with one of the
amines replaced with methylamine. T e fluorescence intensity
of he triazole form of DAR-4M does not exhibit a pH-depen-
dence at pH above 4. The fluorescence quantum eﬃciency is
Fig. 1 Mechanism of ﬂuorescent response of probes based on o-diamine
functionality.
Fig. 2 Structures of DAFs and DAF-Ts. Fig. 3 Structu es of DAF-FM and DAF-FM DA.
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increased more than 840-fold after the transformation of DAFs
by NO with a detection limit of 7 nM.
Compared to fluorescein, 4,4-difluoro-4-bora-3a,4a-diaza-s-
indacene (BODIPY) as the advantages similar to chromo-
phores due to its desirable properties, such as high molar
extinction coeﬃcient, high fluorescence quantum eﬃciency
and low sensitivity to pH. In the past decade, Nagano’s group
has devised the probes based on the BODIPY chromophore,
including DAMBO, DAMBO-PH and DAMBOO (Fig. 5). The
fluorescence of these BODIPY derivatives is very weak. When
they react with NO the formation of triazole significantly
increases the fluorescence intensity. The fluorescence
quantum yield of DAMBO-T and DAMBOO-T is comparable to
that of DAR-4M-T while that of DAMBO-PH-T is 1.7 times
higher than that of DAR-4M-T. Importantly, these BODIPY
derivatives are more sensitive than DAFs. For example, the
reaction eﬃciency of DAMBO and DAMBO-PH with NO to form
DAMBO-T and DAMBO-PH-T, respectively, is about 6 times
higher than that of DAF-2, while the increase in fluorescence
of DAMBOO is greater than that of DAMBO. In addition, the
fluorescence of DAMBO-PH-T and DAMBOO-T is almost inde-
pendent of pH from 4 to 12. Thus, these BODIPY derivatives
seem to be promising for imaging NO in living cells.20,21
Zhang’s group also synthesized this compound and named
it as TMDCDABODIPY (Fig. 5), which has the same structure
as DAMBO-PH. Furthermore, TMDCDABODIPY has been used
to image NO generation in both live neuronal cells and vascu-
lar endothelial cells after stimulation with lipopolysaccharide
(LPS) by using an invert fluorescence microscope. The NO
detection limit of this sensor was evaluated to be 0.3 nM.22
Since the concentration of fluorescence probes and their
fluorescent products is one of the key factors for fluorescence
detection in living cells, controlling the leakage of fluorescence
probes and their reaction products from living cells would be
an eﬀective strategy to increase probe sensitivity in living cells.
Thus, dichlorodiaminocalcein (DCl-DA Cal), where the imino-
diacetic acid group is the key element for the intracellular
retention of the probe (Fig. 6a), is also designed based on this
strategy by Nagano’s group.23 When DCl-DA Cal reacts with
NO, the triazole compound, DCl-DA Cal T, emits strong fluo-
rescence. Although this fluorescence increment of DCl-DA is
similar to that of DAF-2 and DAF-4 tested in a cuvette, bioima-
ging experiments show that DCl-DA can visualize much lower
levels of NO from cultured endothelial cells with or without
0.1 μM bradykinin stimulation due to its better intracellular
retention than DAF-2. This study suggests that DCl-DA is suit-
able for the visualization of low levels of NO and for long-term
observation in living cells.23
In comparison with the conventional aforementioned
visible fluorescent probes, near infrared (NIR) fluorescent
probes possess unique advantages for NO visualization ex vivo
and in vivo. For example, NIR photons can penetrate relatively
deeply into tissues and cause less damage to biological
samples. Moreover, high tissue auto-fluorescence originated
Fig. 4 Structures of DARs.
Fig. 5 Structures of DAMBO, DAMBO-PH, DAMBOO, and
TMDCDABODIPY. Fig. 6 Structures of DCl-DA Cal and DAC.
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Figure 9. Strategies for generation of metal-transition probes. The fluorophore displacement (a), which 
accompanies NO binding to form a metal nitrosyl compound and release the ligand entirely or remove a 
chelating arm to a sufficient distance from the metal; the metal reduction (b) where the paramagnetic metal 
center is reduced to a diamagnetic pattern, restoring the fluorescence;(c) the most widely-used tactic of metal-
tran- sition NO probes is implemented through both displacing the fluorophore and reducing the 
paramagnetic metal center by reductive nitrosylation of NO (Li and Wan, 2015). 
 
Thus, fluorescent probes result easier to use associated with spatio-temporal NO 
concentration, moreover this probes have higher sensitivity to NO rather than its 
metabolites while the alternative methods described. Certainly the choice needs to 
be maid basing on the type of the study keeping attention to the quality of the 
samples will be analyze. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OONO−, indicating a superb selectivity of probe 1 toward NO.
The emissive response of probe 1 is pH-independent in a wide
range of pH from 4 to 9. Furthermore, this probe has been suc-
cessfully applied for both intra- and extracellular NO detection
in RAW264.7 cells after the stimulation with LPS and in HeLa
cells supplied by an NO donor, respectively. In addition, it is
particularly worth mentioning that probe 1 directly responds
to NO itself rather than the oxidized NO species, which is
diﬀerent from the aforementioned most organic probes, thus
avoiding complication in NO sensing.
Sun et al.45 developed a new strategy, which utilizes the
interaction of NO with a selenide. They synthesized rhodamine
B selenolactone (RBSe) by incorporating a Se atom into rhoda-
mine B. The reaction of NO with the Se atom of RBSe leads to
the ring-opening of RBSe, which switches on the fluorescence
of RBSe (Fig. 13). In the absence of NO, this probe is only
weakly fluorescent in aqueous buﬀer (pH 7.2). Upon the
addition of NO into the solution of RBSe, a high fluorescence
signal is immediately produced with the maximal emission at
580 nm. A good linearity was found between the increase in
the fluorescence intensity of this probe and the NO concen-
tration in the range of 2.5 to 30 μM with a detection limit of
38 nM. It was also found that RBSe has high selectivity for NO
over other various species such as common inorganic salts,
ROS, NOS, hemoglobin, superoxide dismutase, reduced gluta-
thione, and pyruvic acid at considerable concentrations. In
addition, Ag(I) and Hg(II) at their normal physiological concen-
trations do not influence the measurement of NO. Further-
more, rhodamine B is a more polar zwitterion and thus may
be well-retained in cells. RBSe as a probe for NO sensing can
be applied to physiological experiments such as in HeLa
cells.45 Moreover, RBSe is also an organic-based fluorescent
probe that directly reacts with NO.
3 Metal-based ﬂuorescent probes
There are two major limitations with regard to organic NO
fluorescent indicators. One is that these probes interact with
NO irreversibly. Reversibility is required to investigate tem-
poral–spatial kinetics of NO production in living cells. The
other limitation is that most of these probes react with oxi-
dized NO products and not with NO itself, resulting in the
inability to reflect real-time NO production.
One solution for these problems is to develop metal tran-
sition-based probes.46,47 This is because metals can form
direct and reversible bonds with NO at the metal center or che-
lated ligand atoms. The fundamental structures of such
probes contain a fluorescein modified with an appended
metal-chelating ligand. The incorporated fluorophore can be
quenched by intracellular photoinduced electron transfer and/
or coordination to a paramagnetic or heavy metal ion.
In metal-based probes, three probable strategies are studied
(Fig. 14). The first strategy uses fluorophore displacement reac-
tion (Fig. 14a), which accompanies NO binding to form a
Fig. 13 Possible reaction mechanism of RBSe with NO. (Reprinted with
permission from ref. 45. Copyright 2011 Royal Society of Chemistry.)
Fig. 12 Structure of probe 1 and the NO detection mechanism (Re-
printed with permission from ref. 44. Copyright 2014 Royal Society of
Chemistry.)
Fig. 14 Mechanisms of metal-transition NO detecting probes.
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Aim of the study 
 
Cancer immunotherapy mainly relies on the activation of the host immune system 
against tumors and it encompasses many approaches, such as tumor antigen–
targeted monoclonal antibodies, immunological checkpoint inhibitors, cytokines, 
therapeutic cancer vaccines, and adoptive cell therapy (ACT). In particular, ACT 
consists in the transfusion of autologous tumor-specific T cells into tumor-bearing 
hosts, and to date, it represents a promising and realistic approach for the 
treatment of cancer patients. The effectiveness of ACT depends on several factors 
as the trafficking of adoptively transferred cells at the tumor site and importantly 
it requires overcoming the immunosuppressive tumor microenvironment.  
 
Solid tumors so far accumulate immunosuppressive cells, such as myeloid derived 
suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). MDSCs 
and TAMs are known to suppress T cell–mediated responses against cancer in 
several ways. One is based on the coordinated upregulation and activity of two 
specific enzymes: arginase (ARG1) and nitric oxide synthase type 2 (NOS2 or 
iNOS). At the tumor site, ARG1 induces the depletion of the amino acid L-
arginine that is necessary for T cell activation and proliferation. NOS2 is 
responsible for the generation of nitric oxide (NO) and other reactive nitrogen 
species (RNS). These free radicals are known to impair T cell functions within the 
tumor. Nitric oxide has dual role in cancer biology because it can promote both 
tumor progression as well as tumor regression. NO induces tumor progression and 
metastasis by the direct induction of tumor-cell proliferation, migration and 
invasion, and indirectly through the expression of angiogenic and 
lymphangiogenic factors in tumor cells. On the other hand, high doses of NO have 
cytotoxic effects, which can result in tumor regression and metastasis inhibition. 
This dichotomous behavior mainly depends on the quantity, location, and timing 
of NO production and on the cellular sensitivity to this radical.   
 
Therefore, the primary aim of this study was to investigate and characterize the 
impact of NOS2 on ACT, paying particular attention to NO, as its principal 
product. To this purpose, we performed in vivo experiments of ACT in either wild 
type or Nos2 knock-out mouse models, challenged with a tumor cell line 
expressing the OVA antigen.   
Instrumental for dissecting the role of NO in ACT was the setting of a valuable 
tool to monitor in real-time NO release by confocal microscopy on viable tumor 
slices after T cell interaction. Specifically, we focused our attention to 
characterize the phenotype and functions of the specific cell population, 
responsible for NO induction following ACT in tumor-bearing hosts. Finally, to 
better characterize the molecular profile of this cell population, using a NO 
specific probe, we set-up a method to isolate this cell population from excised 
tumors by cell sorting. 
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Materials and Methods 
 
Mice 
C57BL/6 (WT), congenic CD45.1 (Ly5+) and OT-I transgenic mice were 
purchased from Charles River. The OT-1 mice in C57BL/6 background bear a 
transgenic T cell receptor, which allows the recognition of ovalbumin residues 
OVA257-264 in the context of H2Kb. Pmel-1 transgenic mice in C57BL/6 
background, which bear a Vα1Vβ13 H-2b restricted TCR specific for murine 
melanoma peptide gp10025-33 on CD8+ T lymphocytes, were provided by Dr. N. 
Restifo (Surgery Branch, National Institutes of Health, Bethesda, MD).  
Nos2-/- mice, Cd40lg-/- mice (B6.129S2-Cd40lgtm1Imx/J) and Tnfrsf5-/- mice 
(B6.129P2-Cd40tm1Kik/J) were all purchased from Jackson Laboratories. In this 
text for convenience Nos2-/- mice were named NOSKO, Cd40lg-/- mice were 
named CD40LKO and Tnfrsf5-/- mice were named CD40KO 
Experiments were performed according to the national guidelines and approved 
by the local ethics committee. 
 
Cell culture 
EG7-OVA (H-2b) cell line was derived from OVA-transfected EL4 thymoma cell 
line (Moore et al., 1988). Cell lines were grown in DMEM supplemented with 2 
mM l-glutamine, 10 mM HEPES, 20 µM 2-mercaptoethanol, 150 U/ml 
streptomycin, 200 U/ml penicillin, G418 (0,4 mg/ml) and 10% heat-inactivated 
FBS (Invitrogen). Cells were maintained at 37°C in a humidified atmosphere 
containing 5% CO2. Primary cells (myeloid cells sorted from tumors, CD4+ or 
CD8+) were cultured in DMEM supplemented with 2 mM l-glutamine, 10 mM 
HEPES, 20 µM 2-mercaptoethanol, 150 U/ml streptomycin, 200 U/ml penicillin 
and 10% heat-inactivated FBS (Biochrom). Lymphocyte culture was 
supplemented with recombinant IL-2 (20 IU/ml). 
Synthetic peptides  
Peptides: H-2 Kb-restricted OVA epitope (OVA257-264, SIINFEKL), the  
H-2Db-restricted hgp10025-33 epitope (KVPRNQDWL), were all synthesized by 
JPT (JPT, Peptide Technologies, Germany). All lyophilized peptides were 
resuspended in DMSO (Sigma-Aldrich) and stored at –20°C until used. 
 
Tumor challenge and Adoptive cells therapy (ACT) 
C57BL/6 mice were s.c. injected on the right flank with 0,5x106 EG-7-OVA cells. 
Tumor growth was monitored every 2 days by a digital caliper. 7 days later, when 
tumor area reached approximately 200 mm3, mice were transferred i.v. with 0,5 
x106 OVA-I specific CTLs, obtained from OT-I spleens. Briefly, spleens were 
harvested from OT-I mice and mechanically digested using the barrel from a 2 
mL syringe, by pouring through a sterile metal cell-strainer. Splenocytes were 
seeded in 24-well plates in the presence of 1 µg/ml OVA-I peptide (Novartis, 
Basel, Switzerland) and maintained in culture for 7 days with 20 IU/ml IL-2.  
6 hours after ACT, mice were injected i.p. with recombinant IL-2 (30,000 IU). IL-
2 was administrated twice a day for three consecutive days. Mice were euthanized 
when tumors reached 1000 mm3. 
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OVA-I specific CTLs were prepared from OT-I spleens. Splenocytes were plated 
in 24-well plates in presence of 1 µg/ml OVA-I peptide and 20 IU/ml IL-2 
(Novartis, Basel, Switzerland). Cultures were maintained for 7 days in complete 
medium supplemented with 20 IU/ml IL-2. Data were presented as the percentage 
of survival after ACT.  
 
Tumor dissociation 
Mice were euthanized and tumors were surgically collected. Tumors were cut in 
small pieces with a scissor; pieces were covered with a digestive solution 
composed of collagenase IV (1 mg/ml) hyaluronidase (0,1 mg/ml) and DNase 
(0,03 KU/ml) and incubated at 37°C; every 10 minutes tumors were mechanically 
processed using a 5 ml pipette. After 1 hour, cells were collected and washed in 
complete medium twice to remove all digestive solution.  
 
Cytofluorimetric staining and analysis  
Cells isolated from tumors and spleens were washed in PBS and incubated with 
anti-Fc-γ receptor for 10 minutes at 4 °C to reduce unspecific binding. Samples 
were then stained with antibodies or relative isotype controls for 20 minutes at 
4°C, washed in PBS and finally resuspended in 300 µl of PBS for flow citometry. 
The antibodies used were: anti-CD11b PE-Cy7 (clone M1/70, BD catalogue no. 
552850), anti-LY6G APC-Cy7 (clone 1A8, BD catalogue no. 560600), anti-
CD11c APC (clone HL3, BD catalogue no. 550261), anti-I-A/I-E PerCP-Cy5.5 
(clone M5/114.15.2, BD catalogue no. 562363), anti-TNFα FITC (clone MP6-
XT22, BD catalogue no. 554418), anti-CD45.1PE (clone A20, BD catalogue no. 
12-0453-83), anti-CD8 PerCP-Cy5.5 (clone 53-6.7, BD catalogue no. 45-0081-
82), anti-LY6C eFluor 450 (clone HK1.4, BD catalogue no. 48-5932-82), anti-
F4/80 FITC (AbDSerotec, clone CI:A3-1, catalogue no. MCA497FB), 
FAB5538PRabbit anti-mouse NOS2 (Abcam, polyclonal catalogue no.15323).  
To analyze the intracellular staining of NOS2, anti-rabbit Rhodamine Red X 
antibody (Jackson Immune Research, catalogue no. 711-295-152) was used. BD 
Citofix/Cytoperm Kit was used for intracellular staining. TNF and INF-γ were 
detected using anti-TNFα FITC (clone MP6-XT22, catalogue no. 554418) and 
anti-INF-γ FITC (clone XMG1.2, catalogue no. 554418) both from BD. Aqua 
Live/Dead®dye (Invitrogen) was used to analyze cell viability. Flow data were 
acquired with a LSRII FACS (BD Biosciences) and analyzed with FlowJo (Tree 
Star, Inc.) software. 
 
Cell sorting  
Total cell suspension from tumors were stained with: anti-CD11b PE-Cy7, anti-
LY6G APC-Cy7, anti-I-A/I-E PerCP-Cy5.5, anti-LY6C eFluor 450, anti-F4/80 
FITC for 20 minutes; cells were washed and resuspended in FACS buffer (PBS, 
EDTA 0.5 mM, FBS 3%, 150 U/ml streptomycin, 200 U/ml penicillin) and sorted 
using FACS Aria® (BD Biosciences).  
 
NO detection within viable tumor slices 
C57BL/6, NOS2 KO, CD40L KO and CD40KO mice were s.c. injected with 0.5 
× 106 EG7-OVA cells. At day 7, tumors were dissected, embedded in 6% agarose 
and cut on vibratome (Leica, VT1000S) to obtain thick viable tumor slices (250 
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µm). Slices were loaded with the NO fluorescent probe (diaminorhodamine-4M 
AM; Sigma) for 1 hour at 37°C. CFSE-labeled CD8+ T cells (1.2 x 106) were 
added on the top of tumor slices. After 2 hours, tumor slices were fixed with 4% 
PFA for 30 minutes at RT. Nuclei were counterstained with 1 µg/ml ToPRO. 
Slides were mounted with ProLong (Invitrogen) and analyzed by confocal 
microscopy (TCS SP5, Leica). 
For quantitative analysis of NO staining, different and noncontiguous regions of 
interest (50 ROIs) were randomly selected, and DAR-4M AM mean intensity was 
quantified for each ROI. Results were expressed as fold induction over control (no 
CD8+ T cells). Recorded images were processed with Vimmaging developed 
under MATLAB™ (MathWorks, Natick, MA), and WCIFImageJ v1.35. 
 
CFSE cell labeling  
OT-I/CD45.1 splenocytes, EG7 cells (for proliferation assays) and CD8+ T 
lymphocytes, derived from the spleen of either OT-I or Pmel-1 mice (for NO 
detection), were labeled with carboxyfluorescein succinimidyl ester (CFSE, 
CFSE- Cell Trace Kit, Invitrogen Molecular Probe) according to manufacturer’s 
instructions.  
 
Immunomagnetic sorting  
CD11b+ cells were isolated for positive selection from spleens and tumors with 
anti-CD11b MicroBeads (MiltenyiBiotec, Germany). Ly6G- CD11b+ cells were 
isolated from tumors by first depleting Ly6G-positive cells by using the anti-
Ly6G MicroBead Kit (MiltenyiBiotec). The negative fraction, Ly6G-CD11b+ 
cells, was indeed decanted and in some experiments Ly6G-CD11b+ cells were co-
cultured with 0.1x106 CFSE-labeled EG7 cells at 3:1; 2:1; 1:1 ratios for 24 h. 
Spleens and lymph nodes from tumor-free or EG7 tumor-bearing mice were used 
to separate CD8+ T lymphocytes by using CD8α+ T cell isolation negative Kit 
(MiltenyiBiotec). CD4+ naïve T lymphocytes were isolated from spleens of OT-II 
mice using a CD4+ T cell isolation Kit (MiltenyiBiotec). All separations were 
performed according to manufacturer’s instructions by using Midi Macs columns 
(MiltenyiBiotec). Purity of cell populations was evaluated by flow cytometry and 
exceeded 90%.  
 
Antigen presentation assays 
Myeloid cells (CD11b+Ly6G-) from EG7-bearing mice - either treated or not with 
ACT- were co-cultured with 5x104 naïve CD4+ T lymphocytes isolated from OT-
II mice by immunomagnetic cell-sorting as previously described in a U-bottom-96 
well plate for 72h. Supernatants from co-cultures were collected and assessed for 
the concentration of mouse IFN-γ.  
 
ELISA 
Supernatants from co-colture experiments (myeloid cell subpopulations sorted 
from tumors, treated or not with ACT plus T lymphocytes) were collected after 
72h. Than IFN-γ production was measured using mouse IFN-γ ELISA Kit 
sandwich (DY485 R&D Systems, Minneapolis, MN). The assay was performed 
according to manufacturer’s instructions.  
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NO detection on tumor cells by flow cytometry and cell sorting 
Tumors were disaggregated as described above by enzymatic digestion.  In this 
case, the enzymatic mixture was supplemented with 5 µM of the NO fluorescent 
probe DAF- FM Diacetate (4-Amino-5-Methylamino2',7' Difluorofluorescein 
Diacetate) (Invitrogen). Tumor single cell suspension was subsequently washed in 
PBS, resuspended in PBS supplemented with 1% heat-inactivated FBS 
(Invitrogen). Incubated with anti-Fc-γ receptor for 10 minutes at 4 °C to reduce 
unspecific binding. Cells were labeled for 20 min at 4°C with the following 
antibodies:  anti-CD11b PE-Cy7, anti-Ly6C eFluor 450, anti-Ly6G APC-Cy7 and 
finally sorted using FACS ARIA cell-sorter, using the gating strategy showed 
below. 
 
 
 
The population of interest was CD11b+DAF-FM+ Ly6G-
  within live cells. For 
dead cell exclusion, samples were stained with Aqua Live/Dead®dye 
(Invitrogen). 
 
Gene expression  
Total RNA was isolated from CD11b+DAF-FM+
 
Ly6G-
 
cells, isolated from 
tumors at day 3 after ACT using TRIzol reagent (Life Technologies, CA, USA). 
RNA integrity assessed using Agilent-2100-Bioanalyzer (Agilent Technologies, 
CA, USA). cDNA from samples was amplified and total RNA was purified with 
Ovation Pico WTA System V2 (NuGEN, CA, USA). Samples were hybridized to 
Affymetrix Mouse Genome 430 2.0 arrays and scanned with an Affymetrix GCS 
3000 7G scanner. 
 
 
 
Myeloid cell data collection and processing  
Myeloid NO producing cells CD11b+DAF-FM+
 
Ly6G isolated from tumors at 
day3 after ACT were collected and merged with 3 publicly available datasets 
comprising microarray data of tissue macrophages (twelve samples), tissue 
dendritic cells (twelve samples), and monocytic myeloid-derived suppressor cells 
(nine samples). All data were measured on Affymetrix arrays and have been 
downloaded from Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) 
or obtained by the authors of the original publications.  
33"
"
 
 
The complete list of datasets is provided in Table 1. Microarray probe 
fluorescence signals of samples belonging to the same platform were converted to 
expression values using robust multiarray average procedure RMA (Irizarry et al., 
2003) of Bioconductor affy package. Specifically, fluorescence intensities were 
background-adjusted and normalized using quantile normalization. log2 
expression values were calculated using median polish summarization and custom 
chip definition files for a total of 21115 custom probe sets for Mouse Gene 1.0 ST 
Array based on Entrez genes (mogene10st_Mm_ENTREZG version 19.0.0) (Dai 
et al., 2005) and 17856 custom probe sets for Mouse Genome 430 2.0 Array based 
on Entrez genes (Mouse4302_Mm_ENTREZG version 19.0.0). All data analyses 
were performed in R version 3.1.3 using Bioconductor libraries and R statistical 
packages. Microarray data of Tip-DCs are available in GEO and the accession 
number is GSE74427. Data of the myeloid cell collection hybridized on Mouse 
Gene 1.0 ST Array were concatenated with those hybridized on Mouse Genome 
430 2.0 Array, matching 16 742 Entrez gene IDs, i.e. the common identifier of 
custom probe sets in both data sets. A direct merging of raw CEL files, although 
desirable for an efficient removal of batch effects, was unfeasible due to the 
different probe sequences of Mouse Gene 1.0 ST and Mouse Genome 430 2.0 
arrays. The combined matrix was subjected to ComBat (Johnson et al., 2007) to 
remove batch effect. ComBat was applied with default parameters with the 
exception of the adjustment variables that were imputed as a vector of platform 
type labels.  
 
 
  
34"
"
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Complete list of gene expression datasets used in this study and their sources.  
a. Immunological Genome Project (www.immgen.org). b. Lei L, Li H, Yan F, Xiao Y. Hyperlipidemia 
impaired innate immune response to periodontal pathogen porphyromonas gingivalis in apolipoprotein E 
knockout mice.PLoS One 2013;8(8):e71849. c. Edelson BT, KC W, Juang R, Kohyama M et al. Peripheral 
CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic 
cells. J Exp Med 2010 Apr 12;207(4):823- 36.  
Cluster and differential gene expression analysis  
Sample grouping was obtained using hierarchical clustering with Pearson 
correlation and centroid as distance metric and linkage, respectively. The 
expression matrix of the myeloid cell collection were analysed with the 
Significance Analysis of Microarray method (SAM)(Tusher et al., 2001), coded in 
the samrRpackage (http://cran.r- project.org/web/packages/samr/index.html) to 
identify differentially expressed genes in the comparisons between subsets of 
macrophages, dendritic cells, and monocytic myeloid-derived suppressor cells (33 
samples). These genes were identified using the multiclass procedure of sam 
Bioconductor package. The q-value threshold was set to 0, the contrast among the 
GEO series Platform GEO samples Reference 
GSE15907 
 
Mouse 
Gene 1.0 
ST 
 
 
GSM605850, GSM605851, 
GSM605852, GSM605856, 
GSM605857, GSM605858, 
GSM605862, GSM605863, 
GSM605864, GSM538239, 
GSM538240, GSM538241, 
GSM605823, GSM605824, 
GSM605825, GSM854273, 
GSM854274, GSM854275 
 
a 
 
 
Mouse 
Gene 1.0 
ST 
 
 
EA07068_226626, 
EA07068_226627, 
EA07068_226628, 
EA07068_226638, 
EA07068_226639, 
EA07068_226640, 
EA07068_226649, 
EA07068_226650, 
EA07068_226651 
a 
GSE42061 
Mouse 
Genome 
430 2.0 
 GSM1031725, GSM1031726, 
GSM1031727 b 
GSE17322 
 
Mouse 
Genome 
430 2.0 
 GSM433363, GSM433365, 
GSM433367 
 
c 
 
In-house 
 
Mouse 
Genome 
430 2.0 
Tip_DC_A, Tip_DC_B -- 
    
 
 
 
Table S1. Complete list of gene expression datasets used in this study and their sources. 
a. Immunological Genome Project (www.immgen.org). b. Lei L, Li H, Yan F, Xiao Y. Hyperlipidemia impaired innate 
immune response to periodontal pathogen porphyromonas gingivalis in apolipoprotein E knockout mice. PLoS 
One 2013;8(8):e71849. c. Edelson BT, KC W, Juang R, Kohyama M et al. Peripheral CD103+ dendritic cells form a 
unified subset developmentally related to CD8alpha+ conventional dendritic cells. J Exp Med 2010 Apr 12;207(4):823-
36.  
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three classes was imposed to be different, and the SAM multiclass score was set ≥ 
2. The multiclass analysis resulted in a list of 604 differentially expressed genes 
(Table2) among macrophages, dendritic cells, and monocytic myeloid-derived 
suppressor cells.  
 
Gene signature comparisons  
Gene expression profiles of the tissue DCs, tissue MFs, M-MDSC and Tip-DCs 
were compared using the published genes signatures of DCs (Miller et al., 2012), 
MFs (Gautier et al., 2012) and M-MDSCs (Conde et al., 2015).  
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Table 2. Complete list of the genes differentially expressed between tissue dendritic cells, tissue 
macrophages and M-MDSCs.  
 
Generation of polyclonal CD40L KO CD8+ T cells recognizing OVA  
WT and CD40LKO mice were intraperitoneally injected with 100 µg of FGK45.5 
antibody against CD40 (BioXcell, NH 03784-1671 USA), in association with 
with OVA257-264 (SIINFEKL) peptide (200 µg/mouse) administration at the tail 
base and then rubbed with imiquimod (Meda, Sweden). Peptide injections were 
repeated twice every 7 days. 
 
Statistic analysis 
Values are reported as mean ± standard error (SE). Survival experiments are 
reported as Kaplan-Meyer curves and significance was determined with log-rank 
test. Student’s t-test was performed on parametric groups. Values were considered 
significantly with p≤0,05 and are indicated as *=p≤0,05; **=p≤0,01 and 
***=p≤0,001.4 
! Gene!Symbol!
Genes%up%regulated%in%tissue%
MFs%
%
Acp1,% Adh5,% Adss,% Ampd3,%Anxa3,% Anxa4,% App,% Ate1,% Atp1b3,% Atp6v1a,%Glb1,% Bmi1,% Calu,%
Capg,%Casp1,%Cd151,%Scarb2,%Cd37,%Comt,%Ctsd,%Ctsl,%Ctss,%Dpm1,%Ecm1,%Emr1,%Chchd2,%Evi5,%
Ptk2,% Aktip,% Grk5,% Grcc10,% Grn,% Hpse,% Impact,% Itgb1,% Itm2b,% Kif16b,% Anxa1,% Lrp1,% Mgat1,%
Ninj1,% P2rx4,% Ppp3ca,% Pros1,% Pts,% Rab12,% Rab18,% Rabggtb,% Rad17,% Rbpms,% Rxra,% Sorbs3,%
Vps4b,% Smpd1,% Soat1,% Syngr1,% Ube3a,%Map2k5,% Clcn7,% Rcn2,% Add3,% Naglu,% Spg21,% Rnf11,%
Timm10,% Pdlim4,% Fbxw7,%Nus1,% Camk1,% Ifi27,% Vamp4,% Rragc,% Golga4,% Akr1e1,%Nagk,% Apip,%
Serinc1,% Socs5,% Vapb,% Sec11a,% Pf4,% Bcam,% Ccdc126,% Krcc1,% Ndfip1,% Zak,% Ogfod3,% Ahnak,%
Pgpep1,% Tceanc2,% Aggf1,% Hiatl1,% Uba5,% Acot13,% Dnajc10,% Mfsd1,% 2610002M06Rik,% Ift27,%
Ptgr1,% Dynlt3,% Herc4,% Abhd5,% Saysd1,% Mrpl18,% Mrpl24,% Pcnxl4,% Fam114a2,% Caap1,% Yipf4,%
1600012H06Rik,% Col4a3bp,% Tsr3,% Steap3,% Tmem140,% Lamtor5,% Ak8,% Mcts1,% Snx4,% Snx24,%
Afg3l2,% Trim32,% Mettl7a1,% 2010107E04Rik,% Fra10ac1,% March8,% Cdadc1,% Paqr7,% Fbxl20,%
Slc16a10,%Tmem87b,%Tmem55a,%Adipor1,%Zfp839,%Fblim1,%Gorasp1,%Zfp943,%Arhgap12,%Nln,%
Zdhhc20,%Snrnp35,%Abca6,%Glt8d1,%Mtif2,%Spopl,%Arsk,%Kidins220,%Stxbp5,%Fam20c,%Sacm1l,%
Fam126a,%Emc9,%Gopc,%Rabif,%Clp1,%Rusc2,%Slc44a1,%Zfp120,%Slc16a6,% Jkamp,%Cdk20,%Ano6,%
Mat2b,% Slc35b3,% Cds2,% Elac1,% Bloc1s4,% Acap3,% Slc25a36,% Kbtbd2,% D15Ertd621e,% Pank3,%
Tmem18,%Cd300a,%Cd300ld,%Gm527,%Zfp758,%Tbc1d24,%Fez2,%Pggt1b,%Rab3gap1,%BC003331,%
Ndufs1,% Dolk,% Sestd1,% Slc25a24,% Ppp4r2,% Pyroxd1,% Zfp790,% Tmem159,% BC030336,% Zfp958,%
Slc36a4,%Tmem205,%Zbtb6,%Dagla,%Mbtps2,%Flnb,%Nt5dc1,%Plekhm1,%Slc38a6,%Wfdc17%
%
Genes%up%regulated%in%tissue%
DCs%
%
Adam19,% Asgr2,% Cd34,% Mark2,% Fyn,% H2_Oa,% H2_Ob,% Hivep2,% Il10ra,% Il18rap,% Napsa,% Klrd1,%
Lrrfip1,% Ltb,% Pak1,% Rel,% Ccl22,% Ccl4,% Skil,% Slc2a3,% Spn,% Zyx,% Gadd45g,% Icosl,% Tbc1d8,% Gps2,%
Fam129a,%Fam107b,%Abhd15,%Slc38a2,%Dusp16,%Tbc1d9,%Taf4b,%Ddit4,%Sesn3,%Rnase6,%Sf3b1,%
Kmo,% Slamf9,% Plekhg2,% Spty2d1,% Haao,% Plekha5,% Lmo1,% Elmo1,% Bmp2k,% Dock10,% Mgl2,%
Slc25a25,% Ppp1r16b,% Tspan33,% Elmsan1,% Malt1,% Itga8,% Nfkbid,% Arhgef40,% Gpr4,% Adrbk2,%
Fbrsl1,% Itprip,% Fam71a,%Ctnna1,%Chd1,%Clk1,%Dhx15,%Ddx3x,% Eif3a,% Eps15,%Gas5,%Hfe,% Ikbkb,%
Mcl1,%Ints6,%Rock1,%Sub1,%Uimc1,%Stag1,%Slk,%Top2b,%Zfp62,%Ubl3,%Ddx3y,%Azin1,%Ccnl2,%Srsf4,%
Hnrnph1,% Tspan13,% Sltm,% Rbm25,% Paxbp1,% Dhx40,% Chd1l,% Rraga,% Gtpbp4,% Spag9,% Nipbl,%
Tbc1d5,% Pan3,% Actr3,% Rnd3,% Cyld,% Hnrnpm,% Wsb1,% Phip,% Cd163,% Ddx50,% Zc3h7a,% Rsrc2,%
Zcchc6,%Ubxn7,%Safb2,%Rsf1,%St8sia6,%Chd2,%Tacc1%%
%
Genes%up%regulated%in%M_
MDCs%
%
Aif1,%Aldoc,%Arg2,%Bub1,%Ccnb2,%Ccne1,%Ccne2,%Ccnk,%Cdk1,%Cdh1,%Ch25h,%Plk3,%Cst7,%Atn1,%
Eif4ebp2,% Foxm1,% Cdca3,% Gtpbp1,% Htr7,% Itga5,% Jak3,% Lyn,% Mcm2,% Mcm5,% Nab2,% Ndrg1,%
Nfatc3,% Orc1,% Osm,% Pafah1b3,% Pfn1,% Plau,% Plk1,% Pole,% Psme3,% Ptbp1,% Kif20a,% Rrm2,% Sf3a2,%
Scd2,% Ccl12,% Ccl2,% Ccl7,% Sh3bp1,% Slc2a1,% Aurkb,% Suv39h1,% Tbrg4,% Trp53,% Tyms,% Usp10,%
Med14,% Pald1,% Smtn,% Gtse1,% Ccdc97,% Cdca8,% Cks1b,% Spag5,% Phc2,% Extl3,% Cxcl11,% Ube2j1,%
Aldh18a1,%Fads2,%Gosr2,%Clec4n,%Brd4,%Trem1,%Trem3,%Foxj2,%Gpr35,%Cenpm,%Nacc1,%Fip1l1,%
Asf1b,% Pmf1,% Gatm,% Mastl,% Eri1,% Dcakd,% Ifitm1,% Nabp2,% Mcm10,% Kif18b,% Crtc3,% Nup205,%
Cenpn,%Mvb12b,% P2ry13,% Pgs1,% 8430419L09Rik,%Ocstamp,% Fam46c,%Dhcr24,% Taf1d,%Dcp1a,%
Fads1,% Ppp1r18,% Dtl,% Ticrr,% Btbd19,% Troap,% Olfml3,% Ifi44,% Noc4l,% Eogt,% Pom121,% Shmt2,%
Nusap1,% E2f8,% Slc13a3,% Fanci,% Proser1,% Ncaph,% Ube2d1,% Git1,% Gatad2b,% Eva1b,% Gdpd5,%
Spon1,%2900026A02Rik,%Eme1,%Lsm12,%Aak1,%Zfp384,%Mthfd1l,%Prr11,%Gins2,%Treml2,%Nol4l,%
Htra4,% Nckap5l,% Gpr114,% Opa3,% Gnptab,% Aprt,% Atpif1,% Phb2,% Bsg,% Cdk4,% Cox8a,% Slc25a1,%
Ercc3,% Gamt,% Bloc1s1,% Bscl2,% Hdac3,% Hus1,% Ndufs4,% Ndufv1,%Mrpl40,% Pde6d,% Prep,% Rab5c,%
Polr2j,% Rsu1,% Slc7a7,% Spp1,% Tfec,%Mlx,% Tpi1,% Tsta3,% Vdac1,% Psmc4,% Psmb2,%Mrpl15,%Nagpa,%
Imp4,% Yipf3,% Vps25,% Pde7b,% Commd2,% Sgta,% Dnlz,% Mtx2,% Clpp,% Rcan3,% Nme6,% Eif3i,% Ift20,%
Mrpl19,% Arl2,% Gabarap,% Cript,% 0610007P14Rik,% Repin1,% Trappc2l,% Mrps24,% Nif3l1,% Dap3,%
Atp5d,% Krtcap2,% 1110008L16Rik,% Grina,% Chchd5,% Ndufb9,% Cox16,% Smim8,% Isoc1,% Ccdc90b,%
2310022A10Rik,%Nmnat1,%Rnf181,%Tpgs2,%Spryd4,%Adat2,%Mrpl33,%Kdelr2,%Tbc1d7,%Cuedc2,%
Ndufa10,%Ccdc53,%Snrpd3,%Sdhb,%Ost4,%1700021F05Rik,%Akr1b10,%Slc25a11,%Rps27l,%Fam96a,%
G6pc3,% Phf5a,% Mphosph6,% Cebpzos,% Samm50,% Tmem214,% Gmppa,% Manbal,% Commd10,%
Psmg4,%Med6,% Tmem147,% Polr2f,% Dhdh,% Trnau1ap,%Mad2l2,% Jmjd8,% Zbed3,% Pgm2,% Ppme1,%
Ndufv2,%Cenpv,%Thoc3,%Isca2,%Slc35f6,%Ndufs7,%Malsu1,%Grhpr,%Yif1b,%Desi2,%Ifitm2,%Kremen1,%
Mrpl34,%Kti12,%Zfand2a,%Brk1,%Rars,%Adi1,%Dph3,%Nsun3,%Cyb5r3,%Cox6b1,%Fam57a,%Pip4k2c,%
Parvb,%Cep78,%Tfe3,%Mtmr9,%Fam20b,%Dhrs7b,%E430025E21Rik,%Alg12,%Mettl8,%Psmf1,%Msto1,%
Prune,% Efcab14,% Dera,% Alkbh6,%Mettl22,% Fcgr4,% Ccdc32,% Gdpgp1,% Ttll1,% BC031181,% Heatr2,%
Gm5617%
%
% %
 
Table S2. Complete list of the genes differentially expressed between tissue dendritic cells, tissue macrophages 
and M-MDSCs. 
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Results 
 
The impact of NOS2 on adoptive cell therapy  
ACT represents a promising approach to treat cancer patients. ACT consists in the 
transfer of CD8+ T lymphocytes specific for tumor antigens. The effectiveness of 
this therapeutic approach requires overcoming of the immunosuppressive tumor 
microenviroment, where distinct immune cell subsets as TAMs and MDSCs, 
definitely block T cell functions (Ugel et al., 2015). 
A key inhibitory pathway in the tumor microenvironment involves the 
metabolism of ariginine through regulated expression of ARG1 and 
NOS2(Gabrilovich et al., 2012). Nonetheless, the precise role of ARG1, NOS2 
and their bioproducts in cancer remains controversial. In particular, the contribute 
of NOS2 in either promoting or controlling tumor progression is likely dependent 
on the cell types up-regulating the expression of this enzyme and the relative NO 
concentration within the tumor microenvironment. 
Indeed, we moved to investigate the role of NOS2 and NO in cancer 
immunotherapy.  
Specifically, to understand the role of NOS2 on ACT, we performed in vivo 
experiments in either WT or NOSKO mice models. Indeed, we challenged mice 
with a cell line expressing the ovalbumin (OVA) antigen EG-7-OVA; at day 7, 
when tumor volume reached 100 mm2, we adoptively transferred in vitro 
activated, congenically-marked, OVA-specific CD8+ T cells and we monitored 
animal survival followed by ACT (Figure 1A). We observed a substantial 
impairment of ACT in NOSKO mice; our data showed, indeed, half survival of 
NOSKO mice after lymphocyte infusion (Figure 1B). This result was unexpected, 
especially for the well-known suppressive role of NOS2, which blocks T cell 
proliferation and activity in the tumor microenviroment. 
To clarify these data, we checked by cytofluorimetric analysis the recruitment of 
OVA-specific CD8+ T cells at the tumor site and spleen of tumor-bearing mice 
undergoing ACT. Higher percentages of OVA-specific, CD8+ CD45.1+ T cells 
were recovered in NOSKO compared to WT mice, both in the spleen and tumor 
(Figure 1C). Transferred CD8+ T cells also produced higher amounts of IFNγ in 
NOSKO mice compared to wild type mice in the tumor microenvironment, while 
we observed less activity of CD8+ T cell in the spleens from either WT and 
NOSKO bearing-mice compared with healthy WT (Figure 1D).  
Nonetheless, although the NOS2 deletion significantly enhanced T cell 
recruitment and activity within the tumor, this was not sufficient to improve the 
efficacy of ACT. These data suggest that NOS2 expression represented a non-
redundant and essential element to achieve the therapeutic effect of ACT in 
tumor-bearing hosts.  Taken together these observations indicated that NOS2 is 
necessary for tumor rejection and suggest a remodelling of tumor 
microenviroment after ACT.  
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Figure 1.  The impact of NOS2 on ACT 
(A) Timeline for experimental treatment. WT and NOSKO mice were injected with EG7-OVA cells. At day 
7, mice were either treated or not with OVA-specific, CD8+CD45.1+ lymphocytes obtained from OT-I mice. 
Mice were euthanized i) at day 10 (to perform FACS analysis and cell sorting) or, ii) when the tumor reached 
an area of 200 mm2, for survival experiments. (B) WT and NOSKO EG7-OVA tumor-bearing mice were left 
untreated (n=5) or treated with ACT with OVA-specific CTLs (WT n=20; NOS KO n=18). Long- rank test 
statistic * P<0.05. (C) Percentage of OVA-specific CD8+CD45.1+ lymphocytes in spleens (left) and tumors 
(right) either from WT or NOS KO mice, challenged with EG7-OVA and undergoing ACT. (D) Percentage 
of +CD8+ CD45.1+IFN-γ+ cells from spleens (left) and tumors (right) from either WT or NOSKO mice 
undergoing ACT (N=4), stimulated ex vivo with the OVA peptide. Error bars are mean ± s.d. ***P≤0.001, 
**P≤0.01 and *P≤0.05, unpaired Student t-test.  
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NO production within the tumor microenviroment 
Given the rationale from our in vivo experiments, we hypothesized a possible role 
for NO, as it represents the principal product of NOS2 activity.  At the tumor site, 
NO can either facilitate or inhibit tumor progression and metastasis by direct 
induction of tumor-cell proliferation, migration and invasion, and indirectly 
through the expression of angiogenic and lymphangiogenic factors in tumor cells. 
On the other hand, high doses of NO have cytotoxic effects, which can result in 
tumor regression and metastasis inhibition. This dichotomous behavior mainly 
depends on the quantity, location, and timing of NO production and on the 
cellular sensitivity to this radical (Fukumura et al., 2006).   
Indeed, to better understand which function NO can exert in ACT, we analyzed 
NO dynamics within the tumor microenvironment in the presence or absence of 
tumor-specific T lymphocytes.   To this aim, we set up a technique for NO 
detection in viable tumor slices taking the advantage of the specific fluorescent 
probe DAR-4MAM.  
DAR-4M AM is an organic-based fluorescent NO probes, mostly composed of 
two elements: a NO-reactive moiety and a fluorophore. The NO-reactive moiety 
(an ammine and a methylamine) act as a modulator in the photoinduced electron 
transfer (PeT) mechanism, which quenches the fluorescence of fluorophores 
(rhodamine) until it binds with the NO or NO oxidized products. The ammine and 
methylamine groups are rapidly hidrolyzed by cells’ esterases and after the bound 
with NO the rhodamine became fluorescent. DAR 4M AM florescence is stable 
under intraceullar ph and it can detect little concentration of NO as 7nM (Li and 
Wan, 2015). 
Our protocol is based on the inclusion in agarose of fresh tumors expressing the 
specific antigen OVA. Subsequently, we cut the embedded tumor with the 
vibratome to obtain viable slices of 250µm. Tumor-slices were loaded with DAR-
4M-AM at 5uM and incubate in the presence or absence of CD8+ T lymphocytes, 
either specific or not for the OVA tumor antigen (Figure 2A). Tumor-slices 
loaded or not with T lymphocytes, were incubated for 2 hours at 37°C; at the end 
of the incubation, tumor-slices were fixed mounted and analysed by confocal 
microscopy. For quantitative analysis of NO staining, different and noncontiguous 
regions of interest (50 ROIs) were randomly selected, and DAR-4M AM mean 
intensity was quantified for each ROI. Results were expressed as fold induction 
over control (no CD8+ T cells).  
We applied this method to measure NO production and release in viable tumor 
slices, obtained from either wild type or NOSKO tumor-bearing EG-7-OVA mice 
(Figure 2B).  
Interestingly, we observed that a significant induction of NO release occurred as 
the result of the addition of antigen-specific CD8+ T cells on viable tumor slices. 
On the contrary, the addition of antigen-unrelated T cells to tumor slices did not 
trigger the NO burst. Coherently, our data also confirmed that NOSKO tumor 
slices presented a significant reduction in NO release compared to the wild type, 
even in the presence of activated antigen-specific lymphocytes (Figure 2C).  
Thus our in vitro data suggested that the interaction between activated anti-tumor 
CD8+ T cells within the tumor microenviroment triggered NO release which is 
primarily produced by the NOS2 enzyme, highly express by myeloid cells. 
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Figure 2. NO detection within tumor slices 
(A) At day 7 post implant, EG7 tumors were dissected, embedded in agarose and cut with a vibratome to 
obtain viable tumor slices (250 µm). Slices were loaded with DAR-4M AM probe, which detects NO. CFSE-
labeled T cells specific for either OVA or gp100 antigen were added on the top of tumor slices. After 
incubation, tumor slices were fixed and analysed by confocal microscopy.  
(B) Representative images of NO production after T cell interaction within viable tumor slices. From the left: 
NO production (red) in the presence of OVA-specific CD8+ T cells (green, OVA-CD8), gp100-specific CD8+ 
T cells (green, gp100-CD8) or in the absence of CD8+ T cells (w/o CD8). Top: tumor slices from WT mice; 
bottom: tumor slices from NOS K.O. mice. DAPI  (blue). Scale bar, 50 µm.  
(C) Released NO levels were measured as mean of fluorescence expressed as fold induction over the control 
(w/o CD8). Error bars, mean ± s.e.m. ; (n=12, pooled from 3 independent experiments), *** p ≤0.001, 
unpaired Student t-test analysis.   
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NOS2 and NO shape tumor microenviroment following ACT 
In tumor-bearing hosts, NOS2 enzyme activity is mostly upregulate in myeloid 
cells as TAMs and MDSCs, capable to suppress T cell activity.  Indeed, we 
decided to analyze the myeloid compartment in the tumor microenvironment 
before and after ACT. We first investigated changes in the number and phenotype 
of intra-tumoral myeloid cells. We started looking at the entire myeloid cell 
subset, infiltrating tumors on the day 10-12 post tumor implant and we observed 
no changes on the percentage of tumor-infiltrating CD11b+cells in either WT or 
NOSKO mice (Figure 3A). We thus evaluated changes within the myeloid cell 
fraction. For this pourpouse, we first expanded the phenotypic characterization of 
this cell population by flow cytometry either in wild type or NOSKO mice before 
and after immunotherapy (Figure 3B). Interestingly, we observed an expansion of 
CD11b+NOS2+ cells in wild type tumors, which was absent in NOSKO mice after 
ACT. Moreover, among the CD11b+ Nos2+ cell fraction, we observed an 
increased number of Ly6C+MHCII+ cells with a coincident reduction in F4/80+ 
macrophages (Figure 3B-C), suggesting that NOS2 activity was primarily due to 
the Ly6C+MHCII+ cell fraction. Afterward, we analyzed the functional activity of 
this myeloid cell subset. We focused our attention on WT mouse model, where we 
found the expansion of CD11b+NOS2+ cells after ACT. Indeed, we challenged 
mice with the EG-7-OVA cell line and we sorted CD11b+Ly6C+MHCII+ or 
CD11b+F4/80+ cells from tumors, treated or not with ACT, to perform functional 
assays.  
We first stimulate the two populations with lipopolysaccharide (LPS) to evaluate 
their ability to release TNFα in response to exogenous stimuli (Figure 4A). 
We found that only the CD11b+NOS2+Ly6C+MHCII++ cells were able to secrete 
TNFα after LPS stimulation; we also observed that this capability was higher on 
cells derived from tumors treated with ACT. Since TNFα is a hallmark of 
activated myeloid cells, we took into consideration the cytostatic activity of this 
cell population against tumor cells.  Indeed, we performed co-colture experiments 
by culturing Ly6G-CD11b+ cells - isolated from tumors of mice adoptively 
transferred with tumor-specific CD8+ T lymphocytes- with tumor cells (Figure 
4B). We found that Ly6G-CD11b+ isolated from wild type mice treated with ACT 
showed enhanced cytostatic activity compared to NOSKO mice. The tumoricidal 
action of this myeloid cell subset was accompanied by an increased NOS2 
expression in cells CD11b+Ly6C+MHCII+ and was abrogated in cells isolated 
from NOSKO mice, suggesting that ACT-induced NOS2 activity contributed to 
the antitumor activity in myeloid cells. In addition to tumor killing properties, we 
also evaluated whether the transfer of CD8+ T cells resulted in the antigen 
presentation activity of these cells inside the tumors. ACT triggered the ability of 
intra-tumoral Ly6C+MHCII+ cells to present antigen to naïve, OVA-specific CD4+ 
T cells from OT-II transgenic mice (Figure 4C).  
 
TNFα and NO production, coupled with the antigen presenting cell capacity, as 
well as cell surface marker profile (Figure 3B-3C) suggested that ACT caused the 
accumulation of an anti-tumor population of myeloid cells most similar to 
TNFα/iNOS producing, inflammatory ‘dendritic’ cells, often termed Tip-DCs 
(Aldridge et al., 2009; Serbina et al., 2003). We defined these cells as CD11b+ 
NOS2+Ly6C+MHCII+ and refer to them as Tip-DCs hereafter. 
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Figure 3.  Flow cytometry analysis of myeloid sub-populations within tumor microenviroment 
(A) Percentage of tumor-infiltrating CD11b+cells in either WT or NOSKO mice at day 10 and 21 post-EG7 
tumor implant. (B) Analysis of myeloid sub-populations in tumors treated with ACT. EG7 tumor-bearing, 
WT mice were either untreated (w/o CD8) or treated with ACT (CD8) and cells derived from tumors mass 
were used for analysis. Gating strategy for myeloid populations in CD11b+NOS2+ gate. NOSKO mice were 
used as a specificity control. (C) Quantification of different myeloid subpopulations in the CD11b+NOS2+ 
gate (N=18). 
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Figure 4. Tip-DCs activity 
(A) Cell suspensions from tumors were stimulated or not with LPS; percentage of different myeloid 
subpopulations in CD11b+ gate, (N=6).(B) Diagram indicates the overall experimental design to assess the 
proliferation of tumor cells. Ly6G-CD11b+ cells sorted from WT, NOSKO EG7-OVA tumor-bearing mice, 
either untreated or treated with ACT, co-cultured with CFSE-labeled EG7-OVA cells at the ratios (3:1, 2:1, 
1:1). The percentage of proliferating EG7-OVA cells after co-culture compared to CFSE-labeled, EG7-OVA 
tumor cells cultured without Ly6G-CD11b+ cells is shown. Error bars, mean ± s.d, (n=9, pooled from 3 
independent experiments); *p ≤0.05, unpaired Student t-test analysis. (C) Sorted myeloid subpopulations 
were cultured with naïve CD4+ lymphocytes to evaluate IFN-γ released in supernatants. 
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Isolation of Tip-DCs and gene array characterization 
After the phenotypic characterization of Tip-DC within tumor, we set up a 
protocol to isolate this population from tumors by fluorescence-activated cell 
sorting (FACS) using the NO fluorescent probe DAF-FM (Kojima et al., 1998). 
This probe is essentially no fluorescent until it reacts with NO to form fluorescent 
benzotriazole that can be detected with flow cytometry.  
We sorted CD11b+ DAF-FM+ cells from WT tumors before and after ACT. 
We observed, as we expected, an expansion on CD11b+ DAF-FM+ cells on 
tumors from mice treated with specific CD8+ T cells (Figure 5A), so we 
performed gene array characterization on sorted cells from WT tumors after 
immunotherapy (Figure 5B-E).  
Our in-house Tip-DC samples were collected and merged with 3 publicly 
available datasets comprising microarray data of tissue macrophages (twelve 
samples), tissue dendritic cells (twelve samples), and monocytic myeloid-derived 
suppressor cells (nine samples). All data were measured on Affymetrix arrays and 
have been downloaded from Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo) or obtained by the authors of the original 
publications. Cluster and differential gene expression analysis was obtained using 
hierarchical clustering with Pearson correlation and centroid as distance metric 
and linkage, respectively. 
The expression matrix of the myeloid cell collection were analysed with the 
Significance Analysis of Microarray method (SAM), coded in the samrRpackage 
(http://cran.rproject.org/web/packages/samr/index.html) to identify differentially 
expressed genes in the comparisons between subsets of macrophages, dendritic 
cells, and monocytic myeloid-derived suppressor cells (33 samples). These genes 
were identified using the multiclass procedure of sam Bioconductor package. The 
q-value threshold was set to 0, the contrast among the three classes was imposed 
to be different, and the SAM multiclass score was set ≥ 2. The multiclass analysis 
resulted in a list of 604 differentially expressed genes among macrophages, 
dendritic cells, and monocytic myeloid-derived suppressor cells.  
We found that intra-tumoral Tip-DCs are transcriptionally more similar to tissue 
DCs (DCs) than to monocytic myeloid-derived suppressor cells (M-MDSC), or 
tissue macrophages (MFs). This similarity emerges using both a subset of genes 
differentially expressed between tissue MFs, tissue DCs and M-MDSCs, as well 
as a set of previously described gene signatures specific for DCs, macrophages 
and M-MDSCs. 
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Figure 5.  Tip-DCs isolation and supervised positioning of Tip-DCs 
(A) Analysis of myeloid cells producing NO, from tumors challenged on wild type mice either treated with 
ACT or untreated. Tumor-infiltrating cells were loaded with DAF-FM for NO detection and labelled with 
CD11b antibody.(B-E) Gene expression profile analysis of the myeloid cell collection. An integrated gene 
expression matrix was generated merging transcriptional profiles of Tip-DCs and publicly available 
microarray data of tissue macrophages (MFs), tissue dendritic cells (DCs) and monocytic myeloid-derived 
suppressor cells (M-MDSCs). (B) Supervised positioning of Tip-DCs. Sample clustering using gene 
expression levels of 604 genes differentially expressed between tissue MFs, tissue DCs and M-MDSCs 
highlights that Tip-DCs are transcriptionally more similar to tissue DCs than to M-MDSCs or tissue 
macrophages.(C) Relative gene expression level of DC specific genes in tissue MFs, M-MDSCs, tissue DCs, 
and Tip-DCs. The heat map evidences that DC specific genes are expressed at comparable levels in both DCs 
and Tip-DCs, but not in tissue MFs and M-MDSCs. (D) Same as in (C) for macrophage specific genes(E) 
Same as in (C) for M-MDSC specific gene.  
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CD40-CD40L axis is required for Tip-DCs recruitment and tumor rejection 
after ACT 
One important axis in the initiation and progression of cellular humoral and 
adoptive immunity is CD40-CD40L. Moreover, CD40 agonists induce T cell-
dependent and independent tumor regression in both mice and patients with 
pancreatic cancer (Beatty et al., 2011). Also ligation of CD40 stimulates the 
induction of NOS2 in macrophages via an IFN-γ-dependent mechanism and it is 
therefore potentially important in activating NOS2 in the tumor 
microenvironment. We thus evaluated whether CD40-CD40L axis was necessary 
for NO-mediated immunotherapy. To investigate this issue, we stained viable 
slices from tumors grown in either CD40KO or CD40L KO mice.  
 We observed a significant reduction in NO release following interaction with 
tumor-specific CD8+ T cells from OT-1, on CD40L KO compared to WT mice, 
thus suggesting a role of CD40/CD40L axis on tissue-infiltrating cells to sustain 
NOS2 activation with prevalent role for host CD40L expression (Figure 6A-B). 
To clarify further the role of CD40L expression in the NO induction, we 
performed NO imaging experiments on viable tumor slices from either WT or 
CD40L KO mice, by using polyclonal OVA-specific CD8+ T cells expanded from 
the spleens of either WT or CD40L KO mice (Figure 7A-B). Our data indicated 
that the greatest reduction in NO release was observed when CD40L-deficient 
OVA-specific lymphocytes were added to CD40L KO tumor slices.  
To confirm the specificity of the CD40-CD40L axis in tumor rejection, we 
performed ACT in CD40 KO and CD40L KO mice bearing EG7 tumors and we 
monitored the survival following ACT (Figure 7C). We found that lack of CD40L 
completely abrogated the therapeutic effect while lack of CD40 induced a partial 
benefit. The differences between the phenotypes of the receptor and ligand 
deficiencies are likely attributed to the fact that CD40 only binds CD40L, while 
CD40L has at least two other integrin binding partners that extend its range of 
actions. These findings clearly confirm the involvement of CD40-CD40L axis on 
ACT effectiveness. 
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Figure 6. CD40-CD40L is necessary for NO induction after T cell interaction 
(A) Representative images of NO production after T cell interaction within viable tumor slices. From the left: 
NO production (red) in the presence of OVA-specific CD8+ T cells (green, OVA-CD8), gp100-specific CD8+ 
T cells (green, gp100-CD8) or in the absence of CD8+ T cells (w/o CD8). Top: tumor slices from WT mice; 
center:  tumor slices from CD40KO; bottom: tumor slices from CD40L KO mice. DAPI (blue). Scale bar, 50 
µm. (B) Released NO levels were measured as mean of fluorescence expressed as fold induction over the 
control (w/o CD8). Error bars, mean ± s.e.m. ; (n=12, pooled from 3 independent experiments), *** p ≤0.001, 
unpaired Student t-test analysis.  
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Figure 7. CD40/CD40L is necessary for NO induction and ACT effectiveness 
(A) Representative images of NO production after T cell interaction within viable tumor slices. CFSE-
labeled, polyclonal CD8+ T cells specific for OVA were derived from immunized WT or 
E8IcreXCD40Lflox/flox mice and were incubated with EG7 tumor slices from either WT or CD40L K.O. mice 
from the left: NO production (red) in the presence of polyclonal OVA-specific CD8 cells from WT mice 
(green, polyclonal OVA-CD8 from WT), polyclonal OVA-specific CD8+ cells from CD40L K.O. mice 
(green, polyclonal CD8-OVA from K.O.) or in the absence of CD8+ T cells (w/o CD8). Top: tumor slices 
from WT mice; bottom: tumor slices from CD40L K.O. mice. DAPI (blue). Scale bar, 50 µm. (B) Released 
NO levels were measured as mean of fluorescence expressed as fold induction over the control (w/o CD8). 
Error bars, mean ± s.e.m. ; (n=12, pooled from 3 independent experiments), *** p ≤0.001, unpaired Student t-
test analysis. (C) Survival percentages of WT, CD40 K.O. and CD40L K.O., EG7 tumor-bearing mice either 
untreated (left) or undergoing ACT (right, n=10, mice/group). *P≤0.05 *** p≤0.001, log-rank test. 
 
  
3RO\FORQDO&'29$
IURP:7
ZR&'3RO\FORQDO&'29$
IURP&'/.2
&'/
.2
:7
$
%






 
:7 &'/
.2
)R
OG
LQG
XF
WLR
Q
RY
HU
FR
QW
UR
O
ZR&'
3RO\FORQDO
&'29$
3RO\FORQDO
&'29$
IURP:7
IURP
'D\V
      

R
IV
XU
YLY
DO





 :7&'.2
6XUYLYDOZLWKRXW$&7 6XUYLYDODIWHU$&7
'D\V
     








&
1XFOHL
&'
'$50$0
49"
"
 
 
Discussion 
 
 The success of ACT - based on the infusion of ex vivo expanded tumor 
infiltrating lymphocytes (TILs)- is limited by crucial events as the trafficking of 
adoptively transferred cells to the tumor site (Melero et al., 2014b) and  the highly 
immunosuppressive environment of developing cancer (Shiao et al., 2011). 
At the tumor site, immunosuppressive functions are exerted by distinct cell 
populations as MDSCs and TAMs, that are known to suppress T cell proliferation 
through several direct and indirect mechanisms (Ugel et al., 2015). A master 
event, regulating T cell functionality within tumors, is the alteration of arginine 
metabolism, which is mainly caused by the selective up regulation of ARG1 and 
NOS2 enzymes within malignant tissues. (Gabrilovich et al., 2012; Marigo et al., 
2010). Evidence from animal models and humans indicates that L-arginine 
metabolism is important in physiological, as well as pathological, conditions 
(Gabrilovich et al., 2012). Nonetheless, the precise role of ARG1 and NOS2 and 
their products in cancer remains controversial. 
Indeed, increased NOS2 expression in breast cancer patients is associated with 
poor clinical outcome and decreased survival (Glynn et al., 2010). On the other 
hand, in some human carcinomas the increment of NOS2 correlates with higher 
infiltration of CD4+ and CD8+ T cells after therapy (Klug et al., 2013). The 
relative role of NOS2 mainly relies on the cell types up-regulating the expression 
of this enzyme and the relative NO concentration within the tumor 
microenvironment. 
Effectively, NO may promote tumor progression and metastasis by the direct 
induction of tumor-cell proliferation, migration and invasion, and indirectly 
through the expression of angiogenic and lymphangiogenic factors in tumor cells 
at low concentration. On the other hand, high doses of NO have cytotoxic effects, 
which can result in tumor regression and metastasis inhibition (Fukumura et al., 
2006). 
In line with our previous investigations, we would have expected an improvement 
of ACT in tumor-bearing hosts in which the NOS2 enzyme was totally ablated. 
Interestingly, we found that NOS2 was necessary for the effectiveness of ACT, 
since we observed that the lack of this enzyme increased the number and activity 
of CD8+T cells. The failure of immunotherapy in NOSKO was totally unexpected 
for the well-known suppressive role of NOS2. Our results so far opened a more 
intricate scenarium with new questions to be addressed: why and how NOS2 is 
necessary for the effectiveness of ACT? Does nitric oxide play a key role in T cell 
activity within the tumor microenvironment?  
In order to address these questions, we started by monitoring NO dynamics at the 
tumor site after the addition of tumor specific T lymphocytes.  To this aim, we 
developed a new method to detect in real-time NO production and release within 
viable tumor slices.   The technical advantage of this approach is the use of the 
fluorescent probe diaminorhodamine (DAR 4M –AM), which specifically reacts 
with NO over other potentially interfering molecules, in combination with 
confocal microscopy. On the contrary, the conventional methods applied for NO 
tracking, such as chemiluminescence and spectroscopy, required complicated 
instrumentation and additionally they suffered from low spatial resolution 
tracking (Lim, Xu et al. 2006).  
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Our data clearly demonstrated that antigen-specific T cells are able to trigger NO 
release within the tumor microenvironment. Importantly, we observed an 
impairment of NO after antigen specific T cell addition underlining that NO is 
mainly produced by NOS2 activity in the tumor mass. 
 
After the awareness that NOS2 and NO are required to sustain tumor rejection, we 
focused our attention on which cell population could be responsible of its 
generation at the tumor site.  It is known that NO is a key regulator of myeloid 
inflammatory cells and its production was reported from macrophages but it is 
still debated whether it can also be originated from other immune cell subsets, as 
mast cells and dendritic cells (Predonzani et al., 2015).   
Indeed, we first analyzed the myeloid compartment in tumors before and after 
ACT.  When we analyzed the entire myeloid cell population in tumors, we did not 
find any significant differences in the total CD11b+ cell percentage before and 
after ACT. So, we analyzed the distribution of distinct myeloid subsets within the 
tumor microenvironment before and after ACT.  
Indeed, after ACT, we observed an expansion of a specific population, 
CD11b+NOS2+ Ly6C+MHCII++cells, which was absent in NOSKO mice and wild 
type mice without treatment. Moreover, the lack of F4/80 in this population, a 
specific marker of macrophages, together with the decrement of macrophage 
percentage in tumors after ACT, suggested that they are not responsible for NO 
generation at the tumor site.  Additionally, the lack of the CD11b+NOS2+ 
Ly6C+MHCII++cell subset in either untreated (no ACT) or NOSKO mice 
suggested that ACT was able to induce the up regulation of NOS2 thus triggering 
NO generation, which in turn promotes the reduction of macrophages (F4/80+ 
cells) with a parallel increment of this new subset of cells within the tumor 
microenvironment.  
 
Evidence from our in vivo and in vitro experiments highlighted the anti-tumor 
nature of this newly identified cell subset. This was further confirmed by 
functional assays, showing the ability of this cell population to secrete TNFα after 
stimulation with LPS and their cytostatic ability against tumors cells.  Further 
confirmation of the anti-tumor activity of this subset came from their ability to 
cross-present, antigens, which is crucial for the generation of effector CD8+ T cell 
response (Fehres et al., 2014).  Essentially, all the functional assays performed 
underlined that antitumor activities were exclusive of 
CD11b+NOS2+Ly6C+MHCII+ cells and were enhanced after ACT protocols. 
The immune phenotype, the functional abilities and in particular NO generation 
observed within viable tumor slices, suggested that this intratumoral myeloid 
population, expanded after ACT, closely resembled the TNF/iNOS producing 
dendritic cells also known as Tip-DC, identified under inflammatory conditions or 
infections. Interestingly, the main roles attributed to Tip-DCs are: i) the rapid and 
local activation of T cell responses, for example for the resolution of 
infection(Aldridge et al., 2009; Serbina et al., 2003) and ii) the pro-inflammatory 
activity in psoriatic lesions of patients skin (Chong et al., 2011; Lowes et al., 
2005). A key feature of Tip-DCs is their ability to prime naïve T cells. To further 
characterize the identity of this cell subset, we isolated this population from 
tumors by means of their ability to generate NO. Indeed, we set-up a FACS 
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sorting strategy based on a NO-specific fluorescent probe DAF-FM, an analogue 
of DAR 4M AM, which is more suitable for the flow cytometry approach.  
Indeed, we isolated CD11b+ DAF-FM+ cells from wild type tumors before and 
after ACT, and we subsequently performed gene array profiling on sorted myeloid 
cell subsets. The gene array characterization was performed merging our in-house 
Tip-DC with 3 publicly available datasets comprising microarray data of tissue 
macrophages (twelve samples), tissue dendritic cells (twelve samples), and 
monocytic myeloid-derived suppressor cells (nine samples). All data were 
measured on Affymetrix arrays and have been downloaded from Gene Expression 
Omnibus (http://www.ncbi.nlm.nih.gov/geo) or obtained by the authors of the 
original publications. We found that this intratumoral myeloid population -
expanded after ACT and identified as TNF/iNOS producing cells - was 
transcriptionally more similar to tissue DCs (DCs) than to monocytic myeloid-
derived suppressor cells (M-MDSC), or tissue macrophages (MFs). This 
similarity emerges using both a subset of genes differentially expressed between 
tissue MFs, tissue DCs and M-MDSCs, as well as a set of previously described 
gene signatures specific for DCs, macrophages and M-MDSCs. Indeed, the 
transcriptional correspondence emerged between our cells and inflammatory 
dendritic cells together with their functional activities and immune phenotype, 
allowed us to identify without any doubts this population as Tip-DCs. 
 
Importantly, our study for the first time described and characterized Tip-DCs 
within the tumor microenvironment.  Indeed, our data indicated that Tip-DCs 
beyond the control of infections play additional immune functions as the control 
of tumor growth in the ACT setting.  
The identification and expansion of Tip-DCs in tumors opened important 
questions for cancer immunotherapy: i) how are Tip-DCs involved on tumor 
rejection? ii) how are these cells recruited within the tumor microenvironment? 
iii) are there any possible uses of these cells to improve the outcome of cancer 
immunotherapy? 
 
Considering our results, it is clear that ACT requires the triggering of an intra-
tumoral, virtuous circle where CD8+ T cell recognition of tumor antigen is 
necessary to recruit Tip-DCs and activate them to present tumor antigens, further 
promoting T cell expansion, and trigger their killing activity by TNFα and NO 
production.   A role for NO production in the efficacy of ACT for the treatment of 
skin cancer was previously suggested (Miguel et al., 2010),  but in that context, 
the production of NO was attributed to macrophages, which was excluded in our 
settings. Notwithstanding, the crucial event regulating Tip-DC expansion in 
tumors is the cross talk between these cells and antigen specific T CD8+ 
lymphocytes. Indeed, we investigated the specific mechanism underpinning these 
dynamic interactions.  
 
To this aim, we first analysed the CD40-CD40L axis, since it controls an array of 
pathways at the base of both initiation and progression of cellular and humoral 
adaptive immunity (Summers deLuca et al., 2011). Moreover, CD40 agonists 
induce T cell-dependent and independent tumor regressions in both mice and 
patients with pancreatic cancer (Beatty et al., 2011). Thus, we analysed viable 
tumor slices either from CD40L KO mice or CD40KO mice. We observed a 
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reduction of NO induction on viable slices derived from CD40LKO mice 
compared to the controls. The engagement of CD40-CD40L axis behind NO-
mediated therapy exerted by Tip-DCs was also confirmed by our in vitro 
experiments. Interestingly, our data obtained on viable tumor slices by using 
polyclonal OVA-specific CD8+ T cells expanded from CD40L KO mice, 
suggested that CD40L was provided by tumor infiltrating CD8+ T lymphocytes. 
Finally, our in vivo data showed clearly the involvement of CD40-CD40L axis on 
ACT effectiveness. Indeed we found that the lack of CD40L completely 
abrogated the therapeutic effect while lack of CD40 induced a partial benefit in 
ACT protocols.  
Our data clearly demonstrated an involvement of this axis on NO-mediated tumor 
rejection. In fact, the controversial results of CD40 could be ascribed to the fact 
that CD40 only binds CD40L, while CD40L has at least two other integrin 
binding partners that extend its range of actions (Alaaeddine et al., 2011) . 
Certainly these mechanism needs to be clarify in details with more investigation; 
at the moment, we first identified CD40-CD40L as key pathway in governing the 
interplay between therapeutic anti-cancer T cells and the local 
immunosuppressive microenvironment.  
 
In conclusion, in this study we proposed a new approach to study NO dynamics 
within the tumor microenvironment based on both confocal microscopy and flow 
cytometry. Thanks to this technological advances, we characterized for the first 
time in tumors a new subset of myeloid cells named Tip-DCs, endorsed with anti-
tumor activity, which can be potentially exploited to improve cancer 
immunotherapy. Most significantly, we shed light on new mechanisms regulating 
activated T -myeloid cell interactions occurring at the tumor microenvironment. 
Remarkably, we pointed out NOS2 and NO as principal effectors of tumor killing 
in ACT protocols.   
Our study brought the awareness that NOS2 is fundamental for the effectiveness 
of ACT, opening new perspectives to improve cancer immunotherapy based on 
NOS2/NO modulation in tumors. 
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Abbreviations 
 
ACT: adoptive cell therapy 
ADAM17: disintegrin and metalloproteinase domain-containing protein 17 
ADCC: antibody-dependent cellular cytotoxicity  
APCs: antigen-presenting cells  
ARG1: arginase 1 
CAFs: cancer associated fibroblasts  
CAR: chimaeric antigen receptor therapy  
CDC: complement-dependent cytotoxicity 
cDCs: conventional DCs  
CDP: common DC progenitors  
cNOS: constitutive nitric oxide sintase 
DCs: dendritic cells 
eNOS or NOS3: endothelial  nitric oxide synthase 
FGFs: fibroblasts growth factors  
GAL-9: galectin-9  
GM-CSF: granulocyte macrophage colony stimulating factor  
HGF: hepatocyte growth factor 
HPLC: High Performance Liquid Chromatography 
IL-1: interleukin-1  
IL-2: interleukin 2 
INF-γ: interferon gamma 
iNOS or NOS2: inducible nitric oxide synthase  
LPS: lipopolysaccharide 
mAbs: monoclonal antibodies 
MDP: macrophage/DC progenitor  
MDSCs: myeloid derived suppressor cells  
MHC: major histocompatibility complex proteins 
mtNOS: mithocondrial NO synthase  
NK: natural killer  
NKT: natural killer T cells  
nNOS or NOS1: neural nitri oxide synthase  
NO: nitric oxide 
NOS: nitric oxide synthases  
PAP: prostatic acid phosphatase  
PARP: Poly (ADP-ribose) polymerase 
pDCs: plasmacytoid DCs  
PDGFs: platelet-derived growth factors  
RECIST:  response evaluation criteria in solid tumors 
ROI: region of interest 
RNOS:  reactive nitrogen oxide species  
RNS: reactive nitrogen species 
ROS:  reactive oxygen species 
sCD40L: recombinant soluble CD40L  
SDF1: stromal cell-derived factor 1  
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SOD: superoxide dismutase  
TAAs: tumor-associated antigens  
TAMs: tumor-associated macrophages 
TCR: T cell receptor 
TIL: tumor infiltrating lymphocyte  
Tip-DCs: TNF/iNOS producing dendritic cells  
TLS: tertiary lymphoid structures  
TNFRSF Tumor Necrosis Factor Receptor superfamily  
Treg: regulatory T cells  
VEGF: vascular endothelial growth factors 
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